WO2018075462A1 - Compositions et procédés de traitement et de prévention d'une lésion associée à une greffe - Google Patents
Compositions et procédés de traitement et de prévention d'une lésion associée à une greffe Download PDFInfo
- Publication number
- WO2018075462A1 WO2018075462A1 PCT/US2017/056898 US2017056898W WO2018075462A1 WO 2018075462 A1 WO2018075462 A1 WO 2018075462A1 US 2017056898 W US2017056898 W US 2017056898W WO 2018075462 A1 WO2018075462 A1 WO 2018075462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- complement
- transplant
- amino acids
- seq
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 118
- 238000000034 method Methods 0.000 title claims abstract description 100
- 230000006378 damage Effects 0.000 title claims description 34
- 208000027418 Wounds and injury Diseases 0.000 title claims description 30
- 208000014674 injury Diseases 0.000 title claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 173
- 239000012634 fragment Substances 0.000 claims description 112
- 230000024203 complement activation Effects 0.000 claims description 79
- 230000000295 complement effect Effects 0.000 claims description 74
- 208000024908 graft versus host disease Diseases 0.000 claims description 73
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 72
- 239000003018 immunosuppressive agent Substances 0.000 claims description 52
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 49
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 48
- 108010036949 Cyclosporine Proteins 0.000 claims description 47
- 229930105110 Cyclosporin A Natural products 0.000 claims description 46
- 238000002054 transplantation Methods 0.000 claims description 46
- 206010063837 Reperfusion injury Diseases 0.000 claims description 42
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 41
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 41
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 38
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 32
- 229960002930 sirolimus Drugs 0.000 claims description 32
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 32
- 239000002131 composite material Substances 0.000 claims description 28
- 230000008685 targeting Effects 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 101150018425 Cr1l gene Proteins 0.000 claims description 14
- 239000003246 corticosteroid Substances 0.000 claims description 13
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 11
- 229960002170 azathioprine Drugs 0.000 claims description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 10
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 10
- 229960004397 cyclophosphamide Drugs 0.000 claims description 10
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 10
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 9
- 229960005167 everolimus Drugs 0.000 claims description 9
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 9
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 9
- 229960004584 methylprednisolone Drugs 0.000 claims description 9
- 229960004618 prednisone Drugs 0.000 claims description 9
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 9
- 230000000735 allogeneic effect Effects 0.000 claims description 8
- 210000002216 heart Anatomy 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 6
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 5
- 210000003709 heart valve Anatomy 0.000 claims description 4
- 210000004087 cornea Anatomy 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 238000011287 therapeutic dose Methods 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- 230000004083 survival effect Effects 0.000 abstract description 25
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 229940024606 amino acid Drugs 0.000 description 167
- 235000001014 amino acid Nutrition 0.000 description 167
- 150000001413 amino acids Chemical group 0.000 description 163
- 108090000623 proteins and genes Proteins 0.000 description 89
- 210000001519 tissue Anatomy 0.000 description 84
- 235000018102 proteins Nutrition 0.000 description 79
- 102000004169 proteins and genes Human genes 0.000 description 79
- 210000004027 cell Anatomy 0.000 description 74
- 230000027455 binding Effects 0.000 description 55
- 108090000765 processed proteins & peptides Proteins 0.000 description 53
- 241000699666 Mus <mouse, genus> Species 0.000 description 51
- 108010053085 Complement Factor H Proteins 0.000 description 49
- 102000016550 Complement Factor H Human genes 0.000 description 49
- 210000000056 organ Anatomy 0.000 description 44
- 125000003275 alpha amino acid group Chemical group 0.000 description 43
- 241000282414 Homo sapiens Species 0.000 description 40
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- 238000011282 treatment Methods 0.000 description 40
- 230000000694 effects Effects 0.000 description 39
- 210000001744 T-lymphocyte Anatomy 0.000 description 36
- 102100022133 Complement C3 Human genes 0.000 description 34
- 239000004074 complement inhibitor Substances 0.000 description 34
- 230000005764 inhibitory process Effects 0.000 description 33
- 229940124073 Complement inhibitor Drugs 0.000 description 32
- 108010009575 CD55 Antigens Proteins 0.000 description 31
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 108020001507 fusion proteins Proteins 0.000 description 28
- 102000037865 fusion proteins Human genes 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 210000003491 skin Anatomy 0.000 description 25
- 230000037361 pathway Effects 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 24
- 238000003556 assay Methods 0.000 description 23
- 201000010099 disease Diseases 0.000 description 23
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 241000894007 species Species 0.000 description 23
- 208000007204 Brain death Diseases 0.000 description 22
- 230000004913 activation Effects 0.000 description 22
- 230000008595 infiltration Effects 0.000 description 22
- 238000001764 infiltration Methods 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 21
- 239000013598 vector Substances 0.000 description 21
- 206010052779 Transplant rejections Diseases 0.000 description 20
- 230000001154 acute effect Effects 0.000 description 19
- 210000003205 muscle Anatomy 0.000 description 19
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 230000002950 deficient Effects 0.000 description 17
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 230000001506 immunosuppresive effect Effects 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 230000009467 reduction Effects 0.000 description 15
- 206010062016 Immunosuppression Diseases 0.000 description 14
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 14
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 14
- 102000050019 Membrane Cofactor Human genes 0.000 description 13
- 101710146216 Membrane cofactor protein Proteins 0.000 description 13
- 101100007623 Mus musculus Cr1l gene Proteins 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 230000008021 deposition Effects 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 102000004856 Lectins Human genes 0.000 description 12
- 108090001090 Lectins Proteins 0.000 description 12
- 108010035766 P-Selectin Proteins 0.000 description 12
- 102100023472 P-selectin Human genes 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000002523 lectin Substances 0.000 description 12
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 11
- -1 MAp44 Proteins 0.000 description 11
- 102000001708 Protein Isoforms Human genes 0.000 description 11
- 108010029485 Protein Isoforms Proteins 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 description 10
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 102000044446 human CD46 Human genes 0.000 description 10
- 102000051442 human CD59 Human genes 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 210000000440 neutrophil Anatomy 0.000 description 10
- 102100031506 Complement C5 Human genes 0.000 description 9
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 9
- 239000004473 Threonine Substances 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 8
- 102000004528 Mannose-Binding Protein-Associated Serine Proteases Human genes 0.000 description 8
- 102000012479 Serine Proteases Human genes 0.000 description 8
- 108010022999 Serine Proteases Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 7
- 108700029850 CR2-fH Proteins 0.000 description 7
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 7
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 7
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 7
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 229960001334 corticosteroids Drugs 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000001476 gene delivery Methods 0.000 description 7
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 7
- 102000057391 human CR2 Human genes 0.000 description 7
- 238000003364 immunohistochemistry Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 230000007115 recruitment Effects 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 101100386242 Homo sapiens CD55 gene Proteins 0.000 description 6
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000003289 regulatory T cell Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 description 5
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 5
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 5
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 230000021736 acetylation Effects 0.000 description 5
- 238000006640 acetylation reaction Methods 0.000 description 5
- 230000009435 amidation Effects 0.000 description 5
- 238000007112 amidation reaction Methods 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 102000006834 complement receptors Human genes 0.000 description 5
- 108010047295 complement receptors Proteins 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 102000045512 human CFH Human genes 0.000 description 5
- 229940125721 immunosuppressive agent Drugs 0.000 description 5
- 229940124589 immunosuppressive drug Drugs 0.000 description 5
- 238000002650 immunosuppressive therapy Methods 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007498 myristoylation Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000013823 prenylation Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000003393 splenic effect Effects 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 description 4
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 description 4
- 108010089414 Anaphylatoxins Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101150073986 C3AR1 gene Proteins 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 4
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 4
- 101100327819 Caenorhabditis elegans chl-1 gene Proteins 0.000 description 4
- 206010068051 Chimerism Diseases 0.000 description 4
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 4
- 229920000057 Mannan Polymers 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 108010052926 complement C3d,g Proteins 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229960002224 eculizumab Drugs 0.000 description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 102000046508 human CR1 Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 150000003355 serines Chemical class 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 102000000989 Complement System Proteins Human genes 0.000 description 3
- 108010069112 Complement System Proteins Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940046731 calcineurin inhibitors Drugs 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 108090000062 ficolin Proteins 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 108091006086 inhibitor proteins Proteins 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000005210 lymphoid organ Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002406 microsurgery Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229950003203 pexelizumab Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 102220080600 rs797046116 Human genes 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000011412 Complement 3d Receptors Human genes 0.000 description 2
- 108010023729 Complement 3d Receptors Proteins 0.000 description 2
- 101710184994 Complement control protein Proteins 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000668170 Homo sapiens RNA-binding motif, single-stranded-interacting protein 2 Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 101710161855 Methionine aminopeptidase 1 Proteins 0.000 description 2
- 101710103983 Modulator of apoptosis 1 Proteins 0.000 description 2
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical group CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010005642 Properdin Proteins 0.000 description 2
- 102100038567 Properdin Human genes 0.000 description 2
- 102100039690 RNA-binding motif, single-stranded-interacting protein 2 Human genes 0.000 description 2
- 101150105073 SCR1 gene Proteins 0.000 description 2
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 206010060872 Transplant failure Diseases 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008395 clarifying agent Substances 0.000 description 2
- 201000002388 complement deficiency Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 229940119744 dextran 40 Drugs 0.000 description 2
- 229940119743 dextran 70 Drugs 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 108010076560 isospaglumic acid Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000003818 metabolic dysfunction Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940055944 soliris Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108010036927 trypsin-like serine protease Proteins 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YPGMOWHXEQDBBV-QWWZWVQMSA-N (4S,5S)-1,2-dithiane-4,5-diol Chemical compound O[C@@H]1CSSC[C@H]1O YPGMOWHXEQDBBV-QWWZWVQMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- AASYSXRGODIQGY-UHFFFAOYSA-N 1-[1-(2,5-dioxopyrrol-1-yl)hexyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(CCCCC)N1C(=O)C=CC1=O AASYSXRGODIQGY-UHFFFAOYSA-N 0.000 description 1
- SGVWDRVQIYUSRA-UHFFFAOYSA-N 1-[2-[2-(2,5-dioxopyrrol-1-yl)ethyldisulfanyl]ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCSSCCN1C(=O)C=CC1=O SGVWDRVQIYUSRA-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 description 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical group N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- QRYXYRQPMWQIDM-UHFFFAOYSA-N 3-benzoyl-3-(2,5-dioxopyrrol-1-yl)-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1(C(=O)C=1C=CC=CC=1)N1C(=O)C=CC1=O QRYXYRQPMWQIDM-UHFFFAOYSA-N 0.000 description 1
- RANONBLIHMVXAJ-UHFFFAOYSA-N 4-hydroxycyclophosphamide Chemical compound OC1CCOP(=O)(N(CCCl)CCCl)N1 RANONBLIHMVXAJ-UHFFFAOYSA-N 0.000 description 1
- NEEVCWPRIZJJRJ-LWRDCAMISA-N 5-(benzylideneamino)-6-[(e)-benzylideneamino]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound C=1C=CC=CC=1C=NC=1C(=O)NC(=S)NC=1\N=C\C1=CC=CC=C1 NEEVCWPRIZJJRJ-LWRDCAMISA-N 0.000 description 1
- 208000023761 AL amyloidosis Diseases 0.000 description 1
- 241001316595 Acris Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
- 101710199744 Anionic trypsin-2 Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101150071803 CR2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 101710155594 Coiled-coil domain-containing protein 115 Proteins 0.000 description 1
- 102100023661 Coiled-coil domain-containing protein 115 Human genes 0.000 description 1
- 108010078018 Complement C3d Proteins 0.000 description 1
- 108090000044 Complement Factor I Proteins 0.000 description 1
- 102100035431 Complement factor I Human genes 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 229940093817 Convertase inhibitor Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241001146209 Curio rowleyanus Species 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100025721 Cytosolic carboxypeptidase 2 Human genes 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 238000011771 FVB mouse Methods 0.000 description 1
- 208000028771 Facial injury Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 102000048120 Galactokinases Human genes 0.000 description 1
- 108700023157 Galactokinases Proteins 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241001149669 Hanseniaspora Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000678845 Homo sapiens Acyl carrier protein, mitochondrial Proteins 0.000 description 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101100440311 Homo sapiens C5 gene Proteins 0.000 description 1
- 101100496569 Homo sapiens C6 gene Proteins 0.000 description 1
- 101100167771 Homo sapiens C9 gene Proteins 0.000 description 1
- 101000749897 Homo sapiens Complement component C8 gamma chain Proteins 0.000 description 1
- 101000932634 Homo sapiens Cytosolic carboxypeptidase 2 Proteins 0.000 description 1
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010023201 Joint contracture Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- PNIWLNAGKUGXDO-UHFFFAOYSA-N Lactosamine Natural products OC1C(N)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 PNIWLNAGKUGXDO-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000015930 Lon proteases Human genes 0.000 description 1
- 108050004171 Lon proteases Proteins 0.000 description 1
- 102100040788 Lutropin-choriogonadotropic hormone receptor Human genes 0.000 description 1
- 101150064138 MAP1 gene Proteins 0.000 description 1
- 101150104297 MASP1 gene Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101000737564 Mus musculus Complement factor H Proteins 0.000 description 1
- 101001033011 Mus musculus Granzyme C Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100497534 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CUB1 gene Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102100032491 Serine protease 1 Human genes 0.000 description 1
- 101710151387 Serine protease 1 Proteins 0.000 description 1
- 101710151381 Serine protease 2 Proteins 0.000 description 1
- 101710151386 Serine protease 3 Proteins 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 102100034392 Trypsin-2 Human genes 0.000 description 1
- 102100034396 Trypsin-3 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000012840 University of Wisconsin (UW) solution Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101000649206 Xanthomonas campestris pv. campestris (strain 8004) Uridine 5'-monophosphate transferase Proteins 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 238000011230 antibody-based therapy Methods 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 201000008560 complement component 3 deficiency Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 108010027437 compstatin Proteins 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 239000012969 di-tertiary-butyl peroxide Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- LNGNZSMIUVQZOX-UHFFFAOYSA-L disodium;dioxido(sulfanylidene)-$l^{4}-sulfane Chemical compound [Na+].[Na+].[O-]S([O-])=S LNGNZSMIUVQZOX-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001282 glomerular podocyte Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000049478 human CR1L Human genes 0.000 description 1
- 102000045735 human NDUFAB1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000002602 induced regulatory T cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- DOVBXGDYENZJBJ-ONMPCKGSSA-N lactosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOVBXGDYENZJBJ-ONMPCKGSSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003018 neuroregenerative effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 108010003052 omptin outer membrane protease Proteins 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 230000000671 osmolytic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 239000006176 redox buffer Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 102220191892 rs199825512 Human genes 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical class [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- Tx organ or tissue transplantation
- toxicity of immunosuppressive drugs is a serious concern since they can cause organ damage, metabolic dysfunction, cancer, and an increase in susceptibility to infection.
- An important goal of Tx research is the development of strategies to minimize immunosuppression.
- One approach being investigated to achieve this is the targeted delivery of immunosuppressive drugs to allografts, which by increasing drug bioavailability permits lower dosing and a reduction in systemic levels of immunosuppression.
- transplantation is an accepted surgical approach for face or limb replacement, and Tx of composite tissue is required since such injuries involve multiple tissues.
- Reconstructive surgery involving vascularized composite (VC) allotransplantation (VCA) is an emerging field, with about 150-200 procedures having been performed since the first successful hand transplant in 1998 (Dubernard et al., 1999, Lancet, 353(9161): 1315-1320).
- tissue transplantation such as VCA
- VCA tissue transplantation
- An increased concern for this type of Tx is the toxicity of immunosuppressive drugs that can cause organ damage, metabolic dysfunction, cancer, and an increase in susceptibility to infection. These toxicities are applicable for all transplant patients, and an important goal in all Tx research, is the development of strategies to minimize immunosuppression.
- graft rejection is principally dependent on T cells, there are other immune factors that can increase graft antigenicity leading to a strengthening of the rejection response.
- IRI ischemia reperfusion injury
- BDI brain death induced injury
- the present invention provides a composition treating or preventing an injury associated with transplantation.
- the present invention provides a composition treating or preventing an injury associated with transplantation.
- composition comprises a targeted inhibitor molecule wherein the targeted inhibitor molecule comprises a targeting portion and an inhibitor portion.
- the molecule inhibits the complement pathways.
- the composition comprises a sub-therapeutic dose of an immunosuppressant agent.
- the targeting portion comprises a CR2 protein or fragment thereof.
- the inhibitor portion comprises at least one selected from the group consisting of FH, MCP, DAF, Cny, MAp44, CD59, and CR1.
- the immunosuppressant agent comprises an agent selected from the group consisting of cyclosporine A, azathioprine, a corticosteroid including prednisone, and methylprednisolone, cyclophosphamide, FK506, and an mTOR inhibitor selected from a group consisting of rapamycin, sirolimus, and everolimus.
- the present invention describes a method of treating or preventing an injury associated with transplantation wherein complement is activated.
- the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent.
- the therapeutic agent comprises a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement activation.
- the transplant is a vascularized composite allograft, heart transplant, kidney transplant, liver transplant, lung transplant, pancreas transplant, intestine transplant, thymus transplant, musculoskeletal graft, cornea graft, skin graft, heart valve graft, nerves graft or vein graft.
- the transplant is an allogeneic hematopoietic stem cell transplantation.
- the targeting portion comprises CR2 or fragment thereof.
- the inhibitor portion comprises at least one selected from the group consisting of FH, MCP, DAF, Cny, MAp44, CD59, and CR1.
- method further comprises administering to the subject a sub-therapeutic amount of an immunosuppressant agent.
- the immunosuppressant agent comprises an agent selected from the group consisting of cyclosporine A, azathioprine, a corticosteroid including prednisone, and
- methylprednisolone cyclophosphamide
- FK506 an mTOR inhibitor selected from a group consisting of rapamycin, sirolimus, and everolimus.
- the subject has graft versus host disease. In one embodiment, the subject has an ischemia reperfusion injury of the transplant or at risk for developing an ischemia reperfusion injury of the transplant.
- the present invention comprises a method of treating or preventing an injury associated with a transplant comprising administering to a transplant a therapeutically effective amount of a therapeutic agent.
- the therapeutic agent comprises a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement pathways
- Figure 2A through Figure 2C is a set of images depicting IgM and C3d deposition in vascularized allografts isolated from mice 48 h after transplantation.
- Figure 2B illustrates the representative immunohistochemistry images.
- Figure 3 A and Figure 3B is a set of images depicting the effects of complement inhibition on the infiltration of neutrophils and macrophages into grafts.
- Figure 4 is a set of images depicting effect of complement inhibition on the expression of P-selectin in grafts. All grafts were isolated from WT recipient mice with PBS (control) or CR2-crry treatment, CSaR ⁇ ' CSaR " " or C3 _/" recipient mice at 48 hours after transplantation. Expression of P-selectin was examined by
- Figure 6A through Figure 6C is a set of images that depicts the combined CR2-Crry and subtherapeutic cyclosporine A treatment delays graft rejection and reduced T cell infiltration.
- Figure 6B depicts the representative immunohistochemistry images of sections obtained from grafts 7 days post
- Figure 7A and Figure 7B is a set of images depicting the combined CR2- Crry and CsA therapy reducing splenic Tel cell populations.
- FIG. 7B demonstrate a significant reduction in overall number of CD8 + CXCR3 + cells in the combined therapy group, as compared to control and single therapy CR2-Crry and CsA groups.
- CD4 + CXCR3 + T cells were significantly reduced in the combined group, as compared to Tx control. While there was an overall trend to reduced total numbers between combined and CsA alone groups, this did not reach statistical significance.
- n 3 in each group).
- Figure 8A through Figure 8C depicts exemplary CR2-FH constructs.
- Figure 8A illustrates a CR2-FH expression plasmid.
- Figure 8B illustrates a CR2-FH protein with signal peptide for an expression plasmid.
- Figure 8C illustrates a mature CR2-FH protein.
- Figure 9 depicts the amino acid sequence of human CR2 (referred to as
- Figure 10 depicts the amino acid sequence of an exemplary human CR2- FH construct (referred to as SEQ NO: 2).
- Figure 11 depicts exemplary amino acid sequence of mouse CR2 (SEQ ID NO: 1
- Figure 12 depicts an amino acid sequence of an exemplary mouse CR2-
- FH construct (SEQ ID NO: 4).
- Figure 13 depicts C3d deposition at GVHD target organs.
- Figure 14 depicts a structure of CR2-FH and a working hypothesis for
- Figure 15 depicts that deficiency of FB but not Clq/MLB in that host ameliorates GVHD.
- Figure 23 depicts that host alternative complement pathway depletion or systematic CR2-FH treatment effectively suppresses GVHD while preserving GVL.
- Figure 16 depicts mechanisms for GVHD attenuation caused by host alternative complement pathway deficiency.
- Figure 17 depicts the results of the in vitro characterization of Map44- CR2.
- Figure 18, comprising Figure 18A and Figure 18B depicts the results of experiments evaluating the therapy of CR2-Crry in combination with subtherapeutic rapamic.
- Subtherapeutic rapamycin and acute C inhibition synergise to inhibit the development of allograft vasculopathy.
- Figure 18 A Quantification of luminal occlusion.
- Figure 19 comprising Figure 19A through Figure 19D depicts the results of example experiments demonstrating the assessment of IRI damage in vascularized composite allografts from recipients of either living donor or brain dead donor grafts that had either been perfused with UW or UW augmented with CR2-Crry .
- Histological quantification of injury in skin (Figure 19A) and muscle (Figure 19C) of grafts isolated at 48 hours post-transplant. Results are expressed as mean ⁇ SD; n 5 for all groups. ## p ⁇ 0.05 BD vs LD, **p ⁇ 0.05 BD vs BD+CR2-Crry. Representative histological images of skin (Figure 19C) and muscle ( Figure 19D).
- Figure 21 depicts an exemplary nucleic acid sequence and amino acid sequence for mouse CR2-Crry.
- the present invention is directed to compositions and methods for treating or preventing injury associated with tissue transplantation.
- the invention provides for a reduced required dose of immunosuppression to prevent organ/tissue rejection or vasculopathy.
- the present invention provides compositions and methods for treatment, inhibition, prevention or reduction of the inflammatory responses associated with the complement signaling.
- the present invention may treat or prevent injuries such as donor brain death induced injuries (BDI) and ischemia-reperfusion injuries (IRI) that occur is tissue/organ transplants such as vascular composite allografts (VCA) and injuries resulting from graft-versus-host disease (GVHD) that can develop following allogeneic hematopoietic stem cell transplantation (all-HSCT).
- the invention is related to compositions and methods affecting signaling associated with complement and products of complement activation thereof associated with transplants particularly associated with VCA and all-HSCT.
- a potential problem in the translation of a complement inhibitor strategy to the clinic is the immunosuppressive effect of systemic complement inhibition, especially important in a Tx setting where the patient is immunocompromised.
- complement has important roles in homeostatic and physiological functions such immune complex catabolism, clearance of dead and dying cells, tissue repair, modulation of adaptive immunity, neuroregenerative processes and host defense.
- Other important concerns regarding the use of systemic complement inhibition relate to efficacy and biodistribution.
- An approach to alleviate the concerns of systemic inhibition described herein specifically targets complement inhibition to sites of complement activation. In this approach, a fragment of C receptor 2 (CR2) that recognizes the C3d activation product is linked to a complement inhibitor.
- CR2 C receptor 2
- an element means one element or more than one element.
- conjugated refers to covalent attachment of one molecule to a second molecule.
- a “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health continues to deteriorate.
- terapéuticaally effective amount refers to a sufficient amount of an agent to provide the desired biological result. That result can be reduction and/or alleviation of a sign, symptom, or cause of a disease or disorder, or any other desired alteration of a biological system. An appropriate effective amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
- fusion protein refers to two or more peptides, polypeptides, or proteins operably linked to each other.
- “Graft” refers to a cell, tissue, organ or otherwise any biological compatible substrate for transplantation.
- mammals include, but are not limited to, farm animals, sport animals, pets, primates, mice and rats.
- the individual is human.
- the individual is an individual other than human.
- inhibitor means to suppress or block an activity or function relative to a control value.
- the activity is suppressed or blocked by 10% compared to a control value, more preferably by 50%, and even more preferably by 95%.
- nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence.
- the phrase nucleotide sequence that encodes a protein or an RNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).
- polypeptide As used herein, the terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds.
- a protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein's or peptide's sequence.
- Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types.
- Polypeptides include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified
- polypeptides derivatives, analogs, fusion proteins, among others.
- the polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
- pharmaceutically acceptable refers to agents that, within the scope of sound medical judgment, are suitable for use in contact with tissues of human beings and/or animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- subject refers to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein.
- patient, subject or individual is a human.
- sub-therapeutic as used herein means a treatment at a dose known to be less than what is known to induce a therapeutic effect.
- terapéutica as used herein means a treatment and/or prophylaxis.
- a therapeutic effect is obtained by suppression, remission, or eradication of a disease state.
- therapeutic agent use herein refers to any agent that has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect, when administered to a subject.
- an agent is considered to be a therapeutic agent if its administration to a relevant population is statistically correlated with a desired or beneficial therapeutic outcome in the population, whether or not a particular subject to whom the agent is administered experiences the desired or beneficial therapeutic outcome.
- terapéuticaally effective amount means an amount that is sufficient, when administered to a population suffering from or susceptible to a disease, disorder, and/or condition in accordance with a therapeutic dosing regimen, to treat the disease, disorder, and/or condition (e.g., host versus graft disease).
- a therapeutically effective amount is one that reduces the incidence and/or severity of, and/or delays onset of, one or more symptoms of the disease, disorder, and/or condition.
- a therapeutically effective amount does not in fact require successful treatment be achieved in a particular individual.
- a therapeutically effective amount may be that amount that provides a particular desired pharmacological response in a significant number of subjects when administered to patients in need of such treatment. It is specifically understood that particular subjects may, in fact, be “refractory” to a “therapeutically effective amount.” To give but one example, a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable.
- reference to a therapeutically effective amount may be a reference to an amount as measured in one or more specific tissues (e.g., a tissue affected by the disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc.).
- a therapeutically effective agent may be formulated and/or administered in a single dose. In some embodiments, a therapeutically effective agent may be formulated and/or administered in a plurality of doses, for example, as part of a dosing regimen.
- tissue transplantation refers to a transfer of tissue or tissue components from an external source into a recipient (host) individual.
- the external source is an organism (e.g., a living, brain dead, recently dead, or dead organism).
- the external source is an ex vivo or in vitro system.
- a “vector” is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell.
- vectors are known in the art including, but not limited to, linear
- vector includes an autonomously replicating plasmid or a virus.
- the term should also be construed to include non-plasmid and non- viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes, and the like.
- viral vectors include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, lentiviral vectors, and the like.
- ranges throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
- the invention describes a therapeutic composition and method for treating or preventing injury associated with transplantation.
- the invention reduces the required dose of immunosuppression to prevent organ/tissue rejection or vasculopathy.
- the composition comprises a targeted complement inhibitor and an immunosuppressant agent.
- the complement inhibitor is a composite molecule comprised of a targeting portion and an inhibitor portion wherein the composite molecule targets complement signaling.
- the complement-targeting portion comprises CR2.
- the composition comprises a complement-targeted inhibitor and an immunosuppressant agent.
- the composition comprises a sub-therapeutic level of the immunosuppressant agent.
- the sub-therapeutic level of the immunosuppressant agent is a level of the immunosuppressant agent that has little to no efficacy if used alone.
- the immunosuppressant agent comprises cyclosporine A.
- the present invention significantly prolongs graft viability without the need for traditional anti -rejection therapies including but not limited to therapeutic levels of immunosuppression therapy.
- the present invention is based in part on the discovery that CR2-Crry composition efficaciously reduce activation of the complement pathways reducing inflammation in many indications including atherosclerosis, multiple sclerosis and IRI. Accordingly, the present invention relates to compositions and methods for improving the viability of vascular composite allografts (VCA), reducing transplant damage, and reducing the risk to the recipient relating to the side effects around graft rejection including those involving the complement pathway.
- VCA vascular composite allografts
- the present invention relates to a composition used to treat a subject that is a recipient of a transplant.
- the composition modulates complement signaling.
- the composition of the present invention comprises a composite molecule comprising a targeting portion and an inhibitor portion.
- the targeting portion directs the molecule to sites of injury or inflammation, and the inhibitor portion inhibit complement signaling.
- the targeting portion is CR2.
- the inhibitor portion is selected from a list comprising but not limited to Factor H (FH), Crry, DAF, MCP, MAp44, CD59, and CR1.
- the composition is the combination of the composite molecule in addition to a sub-therapeutic amount of an immunosuppressant agent.
- the immunosuppressant therapeutic agent selected from a list of agents comprising cyclosporine A azathioprine, corticosteroids including prednisone, and
- methylprednisolone cyclophosphamide
- FK506 cyclophosphamide
- mTOR inhibitors including rapamycin, sirolimus, and everolimus.
- the complement-targeting portion of the herein described composition is CR2.
- the CR2 portion described herein comprises a CR2 or a fragment thereof.
- CR2 is a protein encoded by the CR2 gene and is involved in the complement system. It binds to iC3b (inactive derivative of C3b), C3dg, or C3d, B cells have CR2 receptors on their surfaces, allowing the complement system to play a role in B-cell activation and maturation.
- CR2 consists of an extracellular portion consisting of 15 or 16 repeating units known as short consensus repeats (SCRs).
- Amino acids 1-20 comprise the leader peptide
- amino acids 23-82 comprise SCR1
- amino acids 91-146 comprise SCR2
- amino acids 154-210 comprise SCR3, amino acids 215-271 comprise SCR4.
- the active site (C3dg binding site) is located in SCR 1-2 (the first 2 N-terminal SCRs). SCR units are separated by short sequences of variable length that serve as spacers. It is understood that any number of SCRs containing the active site can be used.
- the construct contains the 4 N-terminal SCR units.
- the construct includes the first two N-terminal SCRs. In another
- the construct includes the first three N-terminal SCRs.
- the CR2 portion comprises the first two N-terminal SCR domains of CR2. In some embodiments, the CR2 portion comprises the first three N-terminal SCR domains of CR2. In some embodiments, the CR2 portion comprises the first four N-terminal SCR domains of CR2. In some embodiments, the CR2 portion comprises (and in some embodiments consists of or consists essentially of) at least the first two N-terminal SCR domains of CR2, including for example at least any of the first 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 SCR domains of CR2.
- a homologue of a CR2 protein or a fragment thereof includes proteins which differ from a naturally occurring CR2 (or CR2 fragment) in that at least one or a few amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide or fragment), inserted, inverted, substituted and/or derived (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition of glycosylphosphatidyl inositol).
- a CR2 homologue has an amino acid sequence that is at least about 70% identical to the amino acid sequence of a naturally occurring CR2 (e.g., SEQ ID NO: 1, or SEQ ID NO:3), for example at least about any of 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of a naturally occurring CR2 (e.g., SEQ ID NO: l, or SEQ ID NO:3).
- a naturally occurring CR2 e.g., SEQ ID NO: 1, or SEQ ID NO:3
- a CR2 homologue or a fragment thereof preferably retains the ability to bind to a naturally occurring ligand of CR2 (e.g., C3d or other C3 fragments with CR2 -binding ability).
- the CR2 homologue (or fragment thereof) may have a binding affinity for C3d that is at least about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of that of CR2 (or a fragment thereof) .
- the CR2 portion comprises at least the first two N- terminal SCR domains of a human CR2, such as a CR2 portion having an amino acid sequence containing at least amino acids 23 through 146 of the human CR2 (SEQ ID NO: 1).
- the CR2 portion comprises at least the first two SCR domains of human CR2 having an amino acid sequence that is at least about any of 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to amino acids 23 through 146 of the human CR2 (SEQ ID NO: l).
- amino acid sequence that is at least about, for example, 95% identical to a reference sequence (such as SEQ ID NO: 1 or SEQ ID NO: 3) is intended that the amino acid sequence is identical to the reference sequence except that the amino acid sequence may include up to five point alterations per each 100 amino acids of the reference sequence. These up to five point alterations may be deletions, substitutions, additions, and may occur anywhere in the sequence, interspersed either individually among amino acids in the reference sequence or in one or more continuous groups within the reference sequence.
- the CR2 portion comprises part or all of the ligand binding sites of the CR2 protein. In some embodiments, the CR2 portion further comprises sequences required to maintain the three dimensional structure of the binding site.
- Ligand binding sites of CR2 can be readily determined based on the crystal structures of CR2, such as the human and mouse CR2 crystal structures disclosed in U.S. Patent Application Publication No. 2004/0005538.
- the CR2 portion comprises the B strand and B-C loop of SCR2 of CR2.
- the CR2 portion comprises a site on strand B and the B-C loop of CR2 SCR comprising the segment G98-G99-Y100-K101-I102-R103-G104-S105-T106-P107- Y108 with respect to SEQ ID NO: 1.
- the CR2 portion comprises a site on the B strand of CR2 SCR2 comprising position Kl 19 with respect to SEQ ID NO: l . In some embodiments, the CR2 portion comprises a segment comprising V149- F150-P151-L152, with respect to SEQ ID NO: 1. In some embodiments, the CR2 portion comprises a segment of CR2 SCR2 comprising T120-N121-F122. In some embodiments, the CR2 -inhibitor molecule has two or more of these sites.
- the CR2 portion comprises a portion comprising G98-G99-Y100-K101- I102-R103-G104-5105-T106-P107-Y108 and Kl 19 with respect to SEQ ID NO: 1. Other combinations of these sites are also contemplated.
- Inhibitor Portion comprises a portion comprising G98-G99-Y100-K101- I102-R103-G104-5105-T106-P107-Y108 and Kl 19 with respect to SEQ ID NO: 1. Other combinations of these sites are also contemplated.
- the molecules described herein in some embodiments comprise an inhibitor portion comprising a complement modulator, such as a complement inhibitor.
- complement inhibitor refers to any compound, composition, or protein that reduces or eliminates complement activity.
- the reduction in complement activity may be incremental (e.g., a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%), or 90% reduction in activity) or complete.
- a complement inhibitor can inhibit complement activity by at least 10 (e.g., at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 or greater) % in a standard in vitro red blood cell hemolysis assay or an in vitro CH50eq assay.
- the CH50eq assay is a method for measuring the total classical complement activity in serum.
- This test is a lytic assay, which uses antibody- sensitized erythrocytes as the activator of the classical complement pathway and various dilutions of the test serum to determine the amount required to give 50% lysis (CH50).
- CH50 50% lysis
- the percent hemolysis can be determined, for example, using a spectrophotometer.
- the CH50eq assay provides an indirect measure of terminal complement complex (TCC) formation, since the TCC themselves are directly responsible for the hemolysis that is measured.
- TCC terminal complement complex
- the assay is well known and commonly practiced by those of skill in the art. Briefly, to activate the classical complement pathway, undiluted serum samples (e.g., human serum samples) are added to microassay wells containing the antibody-sensitized erythrocytes to thereby generate TCC. Next, the activated sera are diluted in microassay wells, which are coated with a capture reagent (e.g., an antibody that binds to one or more components of the TCC). The TCC present in the activated samples bind to the monoclonal antibodies coating the surface of the microassay wells. The wells are washed and, to each well, is added a detection reagent that is detectably labeled and recognizes the bound TCC. The detectable label can be, e.g., a fluorescent label or an enzymatic label. The assay results are expressed in CH50 unit equivalents per milliliter (CH50 U Eq/mL).
- a capture reagent e.g.,
- the complement inhibitor described herein in some embodiments is a specific inhibitor of the lectin pathway. In some embodiments, the complement inhibitor is a specific inhibitor of the alternative pathway. In some embodiments, the complement inhibitor is a specific inhibitor of the classical pathway.
- the complement inhibitor is a soluble or membrane-bound protein such as, for example, membrane cofactor protein (MCP), decay accelerating factor (DAF/CD55), CD59, mouse complement receptor 1-related gene/protein y (Crry), human complement receptor 1 (CR1) or factor H, or Factor I, or an antibody specific for a component of a complement pathway such as, for example, eculizumab (an anti-CS antibody marketed under the trade name Soliris®), pexelizumab (the antigen-binding fragment of eculizumab), an anti-factor B antibody (such as the monoclonal antibody 1379 produced by ATCC Deposit No.
- MCP membrane cofactor protein
- DAF/CD55 decay accelerating factor
- CD59 mouse complement receptor 1-related gene/protein y
- Crry mouse complement receptor 1-related gene/protein y
- CR1 or factor H or Factor I
- an antibody specific for a component of a complement pathway such as, for example, eculizumab (an anti-CS antibody
- a complement inhibitor may be a small molecule or a linear or cyclic peptide such as, for example, compstatin, N- acetylaspartylglutamic acid (NAAGA), and the like.
- the complement inhibitor is selected from the group consisting of: an anti-C5 antibody, an Eculizumab, an pexelizumab, an anti-C3b antibody, an anti-C6 antibody, an anti-C7 antibody, an anti- factor B antibody, an anti- factor D antibody, and an anti-properdin antibody, a human membrane co factor protein (MCP), a human decay accelerating factor (DAF), a mouse decay accelerating factor (DAF), a human CD59, a mouse CD59, a mouse CD59 isoform B, a mouse Crry, a human CR1, a Factor I, a human factor H, a mouse factor H, and a biologically active fragment of any the preceding.
- MCP human membrane co factor protein
- DAF human decay accelerating factor
- DAF mouse decay accelerating factor
- MCP membrane cofactor protein
- CD46 refers to a widely distributed C3b/C4b-binding cell surface glycoprotein which inhibits complement activation on host cells and serves as a cofactor for the factor I-mediated cleavage of C3b and C4b, including ho mo logs thereof. T.J. Oglesby et al., J. Exp. Med. (1992) 175: 1547-1551.
- MCP belongs to a family known as the regulators of complement activation ("RCA"). Family members share certain structural features, comprising varying numbers of short consensus repeat (SCR) domains, which are typically between 60 and 70 amino acids in length.
- SCR short consensus repeat
- MCP comprises four SCRs, a serine/threonine/proline-enriched region, an area of undefined function, a transmembrane hydrophobic domain, a cytoplasmic anchor and a cytoplasmic tail. It is understood that species and strain variations exist for the disclosed peptides,
- polypeptides, and proteins, and that human MCP or biologically active fragments thereof encompass all species and strain variations.
- SEQ ID NO: 5 represents the full-length human MCP amino acid sequence (see, e.g., UniProtKB/Swiss-Prot. Accession No. P15529).
- Amino acids 1-34 correspond to the signal peptide
- amino acids 35-343 correspond to the extracellular domain
- amino acids 344-366 correspond to the transmembrane domain
- amino acids 367-392 correspond to the cytoplasmic domain.
- amino acids 35-96 correspond to SCR 1
- amino acids 97-159 correspond to SCR 2
- amino acids 160-225 correspond to SCR 3
- amino acids 226-285 correspond to SCR 4
- amino acids 302- 326 correspond to the serine/threonine-rich domain. It is understood that species and strain variations exist for the disclosed peptides, polypeptides, and proteins, and that
- MCP or biologically active fragments thereof encompass all species and strain variations.
- biologically active fragment of MCP refers to any soluble fragment lacking both the cytoplasmic domain and the transmembrane domain, including fragments comprising, consisting essentially of or consisting of 1, 2, 3, or 4 SCR domains, with or without the serine/threonine-rich domain, having some or all of the complement inhibitory activity of the full-length human MCP protein.
- the complement inhibitor portion comprises full-length human MCP (amino acids 35-392 of SEQ ID NO:5), the extracellular domain of human MCP (amino acids 35-343 of SEQ ID NO:5), or SCRs 1-4 of human MCP (amino acids 35-285 of SEQ ID NO:5).
- Decay accelerating factor also referred to as CD55 (DAF/CD55) (SEQ ID NO:6 and SEQ ID NO:7), is an -70 kiloDalton (kDa) membrane-bound glycoprotein which inhibits complement activation on host cells.
- DAF comprises several approximately 60 amino acid repeating motifs termed short consensus repeats (SCR).
- DAF decay accelerating factor
- kDa seventy kilodalton
- SCR short consensus repeat
- GPI glycosylphosphatidylinositol
- DAF protects the cell surface from complement activation by dissociating membrane-bound C3 convertases that are required to cleave complement protein C3 and to amplify the complement cascade. DAF prevents assembly or accelerates decay of both the C3- and C5-convertases of the alternative and classical complement pathways.
- SEQ ID NO: 6 represents the full-length human DAF amino acid sequence
- SEQ ID NO:7 represents the full-length mouse DAF amino acid sequence (see, e.g., UniProtKB/Swiss-Prot. Accession No. Q61475).
- amino acids 1-34 correspond to the signal peptide
- amino acids 35-353 appear in the mature protein
- amino acids 354-381 are removed from the polypeptide after translation.
- amino acids 35-96 correspond to SCR 1
- amino acids 96- 160 correspond to SCR 2
- amino acids 161- 222 correspond to SCR 3
- amino acids 223-285 correspond to SCR 4
- amino acids 287-353 correspond to the O-glycosylated serine/threonine-rich domain.
- the GPI anchor is attached to human DAF at a serine at position 353.
- amino acids 1-34 correspond to the signal peptide
- amino acids 35-362 appear in the mature protein
- amino acids 363-390 are removed from the polypeptide after translation.
- amino acids 35-96 correspond to SCR 1
- amino acids 97-160 correspond to SCR 2
- amino acids 161-222 correspond to SCR 3
- amino acids 223-286 correspond to SCR 4
- amino acids 288-362 correspond to the O-glycosylated serine/threonine-rich domain.
- the GPI anchor is attached to mouse DAF at a serine at position 362. It is understood that species and strain variations exist for the disclosed peptides, polypeptides, and proteins, and that DAF or biologically active fragments thereof encompass all species and strain variations.
- biologically active fragment of DAF refers to any fragment of DAF lacking a GPI anchor and/or the amino acid to which it is attached (i.e., Ser-353), including any fragments of the full- length DAF protein comprising, consisting essentially of or consisting of 1, 2, 3, or 4 SCR domains, with or without the O-glycosylated serine/threonine-rich domain, having some or all the complement inhibitory activity of the full-length DAF protein.
- CD59 refers to a membrane-bound 128 amino acid glycoprotein that potently inhibits the membrane attack complex (MAC) of complement.
- CD59 acts by binding to the C8 and/or C9 components of the MAC during assembly, ultimately preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore at the heart of the MAC.
- CD59 is both N- and O-glycosylated.
- the N-glycosylation comprises primarily bi- or tri-antennary structures with and without lactosamine and outer arm fucose residues, with variable sialylation present at some sites.
- CD59 is anchored in the cell membrane by a glycosylphosphatidylinositol (“GPI”) anchor, which is attached to an asparagine at amino acid 102.
- GPI glycosylphosphatidylinositol
- Soluble forms of CD59 have been produced, but they generally have low functional activity in vitro, particularly in the presence of serum, suggesting that unmodified sCD59 has little or no therapeutic efficacy. See, e.g., S. Meri et al.,
- SEQ ID NO:8 represents the full-length human CD59 amino acid sequence (see, e.g., UniProtKB/Swiss-Prot. Accession No. P13987);
- SEQ ID NO:9 represents the full-length mouse CD59 sequence, isoform A (see, e.g., UniProtKB/Swiss- Prot. Accession No. 055186);
- SEQ ID NO: 10 represents the full-length mouse CD59 sequence, isoform B (see, e.g., UniProtKB/SwissProt. Accession No. P58019).
- amino acids 1-25 of SEQ ID NO:8 correspond to the leader peptide
- amino acids 26-102 of SEQ ID NO: 8 correspond to the mature protein
- amino acids 103-128 of SEQ ID NO:8 are removed after translation.
- the GPI anchor is attached to CD59 at an asparagine at position 102 of SEQ ID NO: 8.
- amino acids 1-23 of SEQ ID NO: 9 correspond to the leader peptide
- amino acids 24-96 of SEQ ID NO: 9 correspond to the mature protein
- amino acids 97-123 of SEQ ID NO: 9 are removed after translation.
- the GPI anchor is attached to CD59 at a serine at position 96 of SEQ ID NO: 9.
- amino acids 1-23 of SEQ ID NO: 10 correspond to the leader peptide
- amino acids 24-104 of SEQ ID NO: 10 correspond to the mature protein
- amino acids 105-129 of SEQ ID NO: 10 are removed after translation.
- the GPI anchor is attached to CD59 at an asparagine at position 104 of SEQ ID NO: 10. It is understood that species and strain variations exist for the disclosed peptides, polypeptides, and proteins, and that CD59 or biologically active fragments thereof encompass all species and strain variations.
- biologically active fragment of human CD59 refers to any fragment of human CD59 lacking a GPI anchor and/or the amino acid to which it is attached (i.e., Asn-102), including any fragments of the full-length human CD59 protein having some or all the complement inhibitory activity of the full-length CD59 protein; and the term “biologically active" fragment of mouse CD59 refers to any fragment of mouse CD59 isoform A or isoform B lacking a GPI anchor and/or the amino acid to which it is attached (i.e., Ser-96 of isoform A, or Asp- 104 of isoform B), including any fragments of either full-length mouse CD59 protein isoform having some or all the complement inhibitory activity of the full-length CD59 protein.
- mae complement receptor 1 -related gene/protein y refers to a membrane-bound mouse glycoprotein that regulates complement activation, including homologs thereof. Crry regulates complement activation by serving as a cofactor for complement factor I, a serine protease which cleaves C3b and C4b deposited on host tissue. Crry also acts as a decay- accelerating factor, preventing the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade.
- SEQ ID NO: 11 represents the full-length mouse Crry protein amino acid sequence.
- Amino acids 1-40 correspond to the leader peptide
- amino acids 41-483 of SEQ ID NO: 11 correspond to the mature protein, comprising amino acids 41-405 of SEQ ID NO : 11 , corresponding to the extracellular domain
- amino acids 427-483 of SEQ ID NO: 11 corresponding to the cytoplasmic domain.
- amino acids 83-143 of SEQ ID NO: 11 correspond to SCR 1
- amino acids 144-205 of SEQ ID NO: 11 correspond to SCR 2
- amino acids 206-276 of SEQ ID NO: 11 correspond to SCR 3
- amino acids 277-338 of SEQ ID NO: 11 correspond to SCR 4
- amino acids 339- 400 of SEQ ID NO: 11 correspond to SCR 5. It is understood that species and strain variations exist for the disclosed peptides, polypeptides, and proteins, and that mouse Crry protein or biologically active fragments thereof encompasses all species and strain variations.
- biologically active fragment of mouse Crry protein refers to any soluble fragment of mouse Crry lacking the transmembrane domain and the cytoplasmic domain, including fragments comprising, consisting essentially of or consisting of 1, 2, 3, 4, or 5 SCR domains, including any fragments of the full-length mouse Crry protein having some or all the complement inhibitory activity of the full- length Crry protein.
- the biologically active fragment of mouse Crry comprises amino acids 85-403 of SEQ ID NO: 11.
- complement receptor 1 refers to a human gene encoding a protein of 2039 amino acids, with a predicted molecular weight of 220 kilodaltons (“kDa”), including homologs thereof.
- the gene is expressed principally on erythrocytes, monocytes, neutrophils, and B cells, but is also present on some T lymphocytes, mast cells, and glomerular podocytes.
- CR1 protein is typically expressed at between 100 and 1000 copies per cell. CR1 is the main system for processing and clearance of complement-opsonized immune complexes.
- CR1 negatively regulates the complement cascade, mediates immune adherence and phagocytosis, and inhibits both the classic and alternative complement pathways.
- the full-length CR1 protein comprises a 42 amino acid signal peptide, an extracellular domain of 1930 amino acids, a 25 amino acid transmembrane domain, and a 43 amino acid C-terminal cytoplasmic domain.
- the extracellular domain of CR1 has 25 potential N-glycosylation signal sequences, and comprises 30 short consensus (“SCR") domains, also known as complement control protein (CCP) repeats, or sushi domains, each 60 to 70 amino acids long.
- SCR short consensus
- CCP complement control protein
- the 30 SCR domains are further grouped into four longer regions termed long homologous repeats ("LHRs"), each encoding approximately 45 kDa segments of the CR1 protein, designated LHR-A, -B, -C, and -D.
- LHRs long homologous repeats
- the first three comprise seven SCR domains each, while LHR-D comprises 9 SCR domains.
- the active sites on the extracellular domain of CR1 protein include a C4b-binding site with lower affinity for C3b in SCRs 1-4 comprising amino acids 42-295, a C3b-binding site with lower affinity for C4b in SCRs 8-11 comprising amino acids 490-745, a C3b-binding site with lower affinity for C4b in SCRs 15-18 comprising amino acids 940-1196, and a Clq-binding site in SCRs 22-28 comprising amino acids 1394-1842.
- SEQ ID NO: 12 represents the full-length human CR1 amino acid sequence
- amino acids 1-41 correspond to the signal peptide
- amino acids 42-2039 correspond to the mature protein, comprising amino acids 42-1971, corresponding to the extracellular domain, amino acids 1972-1996, corresponding to the transmembrane domain, and amino acids 1997-2039, corresponding to the cytoplasmic domain.
- amino acids 42-101 correspond to SCR 1
- 102-163 correspond to SCR2
- amino acids 164-234 correspond to SCR3
- amino acids 236-295 correspond to SCR4
- amino acids 295-355 correspond to SCR5
- amino acids 356-418 correspond to SCR6
- amino acids 419-489 correspond to SCR7
- amino acids 491-551 correspond to SCR8
- amino acids 552- 613 correspond to SCR9
- amino acids 614-684 correspond to SCRIO
- amino acids 686-745 correspond to SCR1
- amino acids 745-805 correspond to SCR12
- amino acids 806-868 correspond to SCR13
- amino acids 869-939 correspond to SCR 14
- amino acids 941-1001 correspond to SCR15
- amino acids 1002-1063 correspond to SCR16
- amino acids 1064-1134 correspond to SCR17
- amino acids 1136-1195 correspond to SCR18
- amino acids 1195-1255 correspond to SCR 19
- amino acids 1256-1318 correspond to SCR 20
- CR1 protein or biologically active fragments thereof encompass all species and strain variations.
- biologically active fragment of CR1 protein refers to any soluble fragment of CR1 lacking the
- transmembrane domain and the cytoplasmic domain including fragments comprising, consisting essentially of or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 SCR domains, including any fragments of the full-length CR1 protein having some or all the complement inhibitory activity of the full-length CR1 protein.
- complement factor H As used herein, the term "complement factor H,” “factor H,” or “FH” refers to complement factor H, a single polypeptide chain plasma glycoprotein, including homologs thereof.
- the protein is composed of 20 conserved short consensus repeat (SCR) domains of approximately 60 amino acids, arranged in a continuous fashion like a string of beads, separated by short linker sequences of 2-6 amino acids each.
- SCR conserved short consensus repeat
- Factor H binds to C3b, accelerates the decay of the alternative pathway C3-convertase (C3bBb), and acts as a cofactor for the proteolytic inactivation of C3b.
- C3bBb alternative pathway C3-convertase
- proteolysis by factor I results in the cleavage and inactivation of C3b.
- Factor H has at least three distinct binding domains for C3b, which are located within SCRs 1-4, SCRs 5- 8, and SCRs 19-20. Each domain binds to a distinct region within the C3b protein: the N- terminal sites bind to native C3b; the second site, located in the middle region of factor H, binds to the C3c fragment and the site located within SCR19 and 20 binds to the C3d region.
- factor H also contains binding sites for heparin, which are located within SCR 7, SCRs 5-12, and SCR 20 of factor Hand overlap with those of the C3b binding sites. Structural and functional analyses have shown that the domains for the complement inhibitory activity of factor H are located within the first four N-terminal SCR domains.
- SEQ ID NO: 13 represents the full-length human factor H amino acid sequence (see, e.g., UniProtKB/Swiss-Prot. Accession No. P08603); SEQ ID NO: 14 represents the full-length mouse factor H amino acid sequence (see, e.g.,
- amino acids 1-18 of SEQ ID NO: 13 correspond to the signal peptide
- amino acids 19-1231 of SEQ ID NO: 13 correspond to the mature protein.
- amino acids 21- 80 of SEQ ID NO: 13 correspond to SCR 1
- amino acids 85-141 of SEQ ID NO: 13 correspond to SCR 2
- amino acids 146-205 of SEQ ID NO: 13 correspond to SCR 3
- amino acids 210-262 of SEQ ID NO: 13 correspond to SCR 4
- amino acids 267-320 of SEQ ID NO: 13 correspond to SCR 5.
- amino acids 1- 18 of SEQ ID NO: 14 correspond to the signal peptide
- amino acids 19-1234 of SEQ ID NO: 14 correspond to the mature protein.
- amino acids 19-82 of SEQ ID NO: 14 correspond to SCR 1
- amino acids 83-143 of SEQ ID NO: 14 correspond to SCR 2
- amino acids 144-207 of SEQ ID NO: 14 correspond to SCR 3
- amino acids 208-264 of SEQ ID NO: 14 correspond to SCR 4
- amino acids 265-322 of SEQ ID NO: 14 correspond to SCR 5.
- biologically active fragment of factor H refers to any portion of a factor H protein having some or all the complement inhibitory activity of the full-length factor H protein, and includes, but is not limited to, factor H fragments comprising SCRs 1-4, SCRs 1-5, SCRs 1-8, SCRs 1-18, SCRs 19-20, or any homolog of a naturally-occurring factor H or fragment thereof, as described in detail below.
- the biologically active fragment of factor H has one or more of the following properties: (1) binding to C-reactive protein (CRP), (2) binding to C3b, (3) binding to heparin, (4) binding to sialic acid, (5) binding to endothelial cell surfaces, (6) binding to cellular integrin receptor, (7) binding to pathogens, (8) C3b co-factor activity, (9) C3b decay- acceleration activity, and (10) inhibiting the alternative complement pathway.
- CRP C-reactive protein
- SEQ ID NO: 15 represents the amino acid sequence for mannose-binding lectin-associated protein of 44kDa (MAp44).
- MAp44 is an alternatively spliced product encoded by the MASP1 gene.
- MAp44 is an inhibitor of lectin pathway activation.
- the inhibitor portion of the targeted molecule described herein comprises a complement inhibitor or biologically active fragment thereof.
- the complement inhibitor is selected from the group consisting of human MCP, human DAF, mouse DAF, human CD59, mouse CD59 isoform A, mouse CD59 isoform B, mouse Crry protein, human CRl, human factor H, or mouse factor H, a Factor I, MAp44 or a biologically active fragment thereof.
- the inhibitor portion comprises full-length human MCP (SEQ ID NO:5).
- the complement inhibitor portion of the targeting construct comprises a biologically active fragment of human MCP (SEQ ID NO:5).
- the biologically active fragment of human MCP is selected from the group consisting of SCRs 1-4 (amino acids 35-285 of SEQ ID NO:5), SCRs 1-4 plus the serine/threonine-rich domain (amino acids 35-326 of SEQ ID NO:5), and the extracellular domain of MCP (amino acids 35-343 of SEQ ID NO:5).
- the inhibitor portion comprises full-length human
- the inhibitor portion comprises a biologically active fragment of human DAF (SEQ ID NO:6).
- the biologically active fragment of human DAF is selected from the group consisting of SCRs 1-4 (amino acids 25-285 of SEQ ID NO:6) and SCRs 1-4 plus the O- glycosylated serine/threonine-rich domain (amino acids 25-353 of SEQ ID NO:6).
- the inhibitor portion comprises full-length mouse DAF (SEQ ID NO:7).
- the inhibitor portion comprises a biologically active fragment of mouse DAF.
- the biologically active fragment of mouse DAF is selected from the group consisting of SCRs 1-4 (amino acids 35-286 of SEQ ID NO:7) and SCRs 1-4 plus the O- glycosylated serine/threonine-rich domain (amino acids 35-362 of SEQ ID NO:7).
- the inhibitor portion comprises full-length human
- the inhibitor portion comprises a biologically active fragment of human CD59 (SEQ ID NO:8).
- the biologically active fragment of human CD59 comprises the extracellular domain of human CD59 lacking its GPI anchor (amino acids 26-101 of SEQ ID NO:8).
- the inhibitor portion comprises full-length mouse CD59, isoform A (SEQ ID NO:9).
- the inhibitor portion comprises a biologically active fragment of mouse CD59, isoform A (SEQ ID NO:9).
- the biologically active fragment of mouse CD59, isoform A comprises the extracellular domain of mouse CD59, isoform A lacking its GPI anchor (amino acids 24-95 of SEQ ID NO:9).
- the inhibitor portion comprises full-length mouse CD59, isoform B (SEQ ID NO: 10).
- the c inhibitor portion comprises a biologically active fragment of mouse CD59, isoform B (SEQ ID NO: 10).
- the biologically active fragment of mouse CD59, isoform B comprises the extracellular domain of mouse CD59, isoform lacking its GPI anchor (amino acids 24- 103 of SEQ ID NO: 10).
- the inhibitor portion comprises full-length mouse Crry protein (SEQ ID NO: 11). In some embodiments, the inhibitor portion comprises a biologically active fragment of mouse Crry protein (SEQ ID NO: l 1). In some embodiments, the biologically active fragment of mouse Crry protein is selected from the group consisting of SCRs 1-5 (amino acids 41-400 of SEQ ID NO: 11) and the extracellular domain of mouse Crry protein (amino acids 41-405 of SEQ ID NO: 11). In one embodiment, the inhibitor portion comprises the biologically active fragment of mouse Crry comprising amino acids 85-403 of SEQ ID NO: 11.
- the inhibitor portion comprises full-length human CR1 protein (SEQ ID NO: 12).
- the t inhibitor portion comprises a biologically active fragment of human CR1 protein (SEQ ID NO: 12).
- the biologically active fragment of human CRl protein is selected from the group consisting of SCRs 1-4 (amino acids 42-295 of SEQ ID NO: 12), SCRs 1-10 (amino acids 42-684 of SEQ ID NO: 12), SCRs 8-11 (amino acids 490-745 of SEQ ID NO: 12), SCRs 15-18 (amino acids 940-1196 of SEQ ID NO: 12), and SCRs 22-28 (amino acids 1394-1842 of SEQ ID NO: 12).
- the inhibitor portion comprises full-length human (SEQ ID NO: 13) or mouse (SEQ ID NO: 14) factor H. In some embodiments, the inhibitor portion comprises a biologically active fragment of human (SEQ ID NO: 13) or mouse (SEQ ID NO: 14) factor H.
- the biologically active fragment of human factor H is selected from the group consisting of SCRs 1-4 (amino acids 21-262 of SEQ ID NO: 13), SCRs 1-5 of factor H (amino acids 21-320 of SEQ ID NO: 13), SCRs 1-8 of factor H (amino acids 21-507 of SEQ ID NO: 13), and SCRs 1-18 of factor H (amino acids 21-1104 of SEQ ID NO: 13).
- the biologically active fragment of mouse factor H is selected from the group consisting of SCRs 1-4 (amino acids 19-264 of SEQ ID NO: 14), SCRs 1-5 of factor H (amino acids 19-322 of SEQ ID NO: 14), SCRs 1-8 of factor H (amino acids 19- 507 of SEQ ID NO: 14), and SCRs 1-18 of factor H (amino acids 19-1109 of SEQ ID NO: 14).
- the biologically active fragment of human (SEQ ID NO: 13) or mouse (SEQ ID NO: 14) factor H comprises (and in some embodiments consists of or consists essentially of) at least the first four N-terminal SCR domains of factor H, including for example, at least any of the first 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or more N-terminal SCR domains of factor H.
- the inhibitor portion comprises MAp44 (SEQ ID NO: 15). In some embodiments, the inhibitor portion comprises a biologically active fragment of MAp44 (SEQ ID NO: 15).
- the inhibitor portion of the targeted molecules is a homolog of any of the complement inhibitors described herein or a biologically active fragment thereof.
- Homologs of the complement inhibitors include proteins which differ from a naturally occurring complement inhibitor (or biologically-active fragment thereof) in that at least one or a few, but not limited to one or a few, amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide or fragment), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition glycosylphosphatidyl inositol).
- homologue of a complement inhibitor may have an amino acid sequence that is at least about 70% identical to the amino acid sequence of a naturally complement inhibitor (e.g., SEQ ID NOs:5-12), for example at least about any of 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%), 97%), 98%), or 99% identical to the amino acid sequence of a naturally occurring complement inhibitor (e.g., SEQ ID NOs:5-15).
- a naturally complement inhibitor e.g., SEQ ID NOs:5-12
- Amino acid sequence identity can be determined in various ways, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGNTM (DNAST AR) software.
- BLAST BLAST-2
- ALIGN ALIGN
- MEGALIGNTM DNAST AR
- a homolog of complement inhibitor retains all the alternative complement pathway inhibitory activity of the complement inhibitor (or a biologically active fragment thereof) from which it is derived. In certain embodiments, the homolog of a complement inhibitor (or a biologically-active fragment thereof) retains at least about 50%, for example, at least about any of 60%, 70%, 80%, 90%, or 95% of the complement inhibition activity the complement inhibitor (or a biologically-active fragment thereof) from which is derived.
- the inhibitor portion comprises an antibody (or an antigen binding fragment thereof) that binds to a complement component, e.g., a complement component selected from the group consisting of CI, Clq, Cis, C2, C2a, C3, C3a, C3b, C4, C4b, C5, C5a, C5b, C6, C7, C8, and C9.
- a complement component selected from the group consisting of CI, Clq, Cis, C2, C2a, C3, C3a, C3b, C4, C4b, C5, C5a, C5b, C6, C7, C8, and C9.
- the complement polypeptides to which the antibodies or antigen binding fragments thereof bind can be, in some embodiments, human polypeptides, e.g., human CI, Clq, Cls, C2, C2a, C3, C3a, C3b, C4, C4b, C5, C5a, C5b, C6, C7, C8, C9, factor B, factor D, or properdin polypeptides.
- human polypeptides e.g., human CI, Clq, Cls, C2, C2a, C3, C3a, C3b, C4, C4b, C5, C5a, C5b, C6, C7, C8, C9, factor B, factor D, or properdin polypeptides.
- the amino acid sequences for the foregoing complement proteins are well-known in the art as are methods for preparing the proteins or fragments thereof for use in preparing an antibody (or antigen-binding fragment thereof) specific for one or more of the
- anti-complement protein antibodies which are suitable for incorporation into the targeted molecules described herein and for subsequent use in any of the methods described herein, are also well known in the art.
- antibodies that bind to complement component C5 and inhibit the cleavage of C5 into fragments C5a and C5b include, e.g., eculizumab (Soliris®; Alexion Pharmaceuticals, Inc.,
- Cheshire, CT and pexelizumab (Alexion Pharmaceuticals, Inc., Cheshire, CT). See, e.g., Kaplan (2002) Curr Opin Investig Drugs 3(7): 1017-23; Hill (2005) Clin Adv Hematol Oncol 3(11):849-50; Rother et al. (2007) Nature Biotechnol 25(11): 1256-1488; Whiss (2002) Curr Opin Investig Drugs 3(6):870-7; Patel et al. (2005) Drugs Today (Bare) 41(3): 165-70; and Thomas et al. (1996) Mol Immunol. 33(17- 18): 1389-401.
- the anti-C5 antibody can bind to an epitope in the alpha chain of the human complement component C5 protein.
- Antibodies that bind to the alpha chain of C5 are described in, for example, PCT application publication no. WO
- the anti-C5 antibody can bind to an epitope in the beta chain of the human complement component C5 protein.
- Antibodies that bind to the C5 beta chain are described in, e.g., Moongkamdi et al. (1982) Immunobiol 162:397; Moongkamdi et al. (1983) Immunobiol 165:323; and Mollnes et al. (1988) Scand 1 Immunol 28:307-312.
- Antibodies that bind to C3b and, for example, inhibit the C3b convertase are also well known in the art.
- PCT application publication nos. WO 2010/136311, WOb2009/056631, and WO 2008/154251 the disclosures of each of which are incorporated herein by reference in their entirety.
- Antagonistic anti-C6 antibodies and anti-C7 antibodies have been described in, e.g., Brauer et al.(1996) Transplantation 61(4):S88-S94 and U.S. patent no. 5,679,345.
- the inhibitor portion comprises an anti-factor B antibody (such as the monoclonal antibody 1379 produced by ATCC Deposit No. PTA- 6230).
- Anti-factor B antibodies are also described in, e.g., Ueda et al. (1987) J Immunol 138(4): 1143-9; Tanhehco et al. (1999) Transplant Proc 31(5):2168-71; U.S. patent application publication nos. 20050260198 and 2008029911; and PCT publication no. WO 09/029669.
- the inhibitor portion comprises an anti-factor D antibody, e.g., an antibody described in Pascual et al. (1990) 1 Immunol Methods 127:263-269; Sahu et al. (1993) Mol Immunol 30(7):679-684; Pascual et al. (1993) Eur 1 Immunol 23 : 1389-1392; Niemann et al. (1984) J Immunol 132(2):809-815; U.S. patent no. 7,439,331; or U.S. patent application publication no. 20080118506.
- an anti-factor D antibody e.g., an antibody described in Pascual et al. (1990) 1 Immunol Methods 127:263-269; Sahu et al. (1993) Mol Immunol 30(7):679-684; Pascual et al. (1993) Eur 1 Immunol 23 : 1389-1392; Niemann et al. (1984) J Immunol 132(2):809
- the inhibitor portion comprises an anti-properdin antibody.
- Suitable anti-properdin antibodies are also well-known in the art and include, e.g., U.S. patent application publication nos. 20110014614 and PCT application publication no. W02009110918.
- the inhibitor portion comprises an anti-MBL antibody.
- Mannose-binding mannan-binding lectin a plasma protein, forms a complex with proteins known as MBL-associated serine proteases (MASPs).
- MBL binds to several monosaccharides that are uncharacteristic of mammalian proteins, e.g., mannose, N-acetylglucosamine, N-acetylmannoseamine, L-fucose and glucose, whereas sialic acid and galactose are not bound.
- MBL-MASP complex When the MBL-MASP complex binds to microorganisms, the proenzymic forms of the serine proteases are activated and mediate the activation of complement components C4 and C2, thereby generating the C3 convertase C4b2b and leading to opsonization by the deposition of C4b and C3b fragments.
- MASP -2 has been shown to cleave C4 and C2, while MASP-1 may be responsible for direct cleavage of C3.
- the functions of MASP-3 and MApl9 are less well understood. Studies have shown a clear link between low levels of MBL and opsonic deficiency, as well as clinical manifestations such as severe diarrhea, chronic hepatitis and HIV infection, and autoimmune disease.
- Anti-mannan-binding lectin antibodies are known in the art (see, e.g., Pradhan et al. (2012) Rheumatol. Int. epublished September, 2012) and commercially available (AbCam).
- the inhibitor portion comprises an anti-MASP antibody.
- MASPs mannan-binding lectin-associated serine proteases
- MASP-1, MASP-2 and MASP-3 mannan-binding lectin-associated serine protease- 1, -2 and -3
- MASP-1 has a histidine loop structure of the type found in trypsin and trypsin-like serine proteases. MASP-1 has been found to be involved in complement activation by MBL. A cDNA clone encoding MASP-1 has been reported that encodes a putative leader peptide of 19 amino acids followed by 680 amino acid residues predicted to form the mature peptide. MASP-2 (MBL-associated serine protease 2) is a serine protease also similar in structure to CI r and CI s of the complement pathway. Like these, and contrary to MASP-1, it has no histidine loop structure of the type found in trypsin and trypsin-like serine proteases. It has been theorized that MASP-1 can cleave C3, generating C3b, which may be deposited on an activated cell or tissue surface
- MASP-2 cleaves C4 and C2, giving rise to the C3 convertase, C4b2b (Thiel et al., Nature, 386:506-10 (1997)).
- the MASP-2 protein comprises of a number of domains namely the CUB1, EGF, CUB2, CCP1, CCP2 and serine protease domains. It is believed that the domain responsible for association with MBL is situated in the N-terminus, whereas the serine protease domain is responsible for the serine protease activity of MASP-2.
- sMAP also known as MApl9
- MApl9 is a 19 kd is derived from the same gene as MASP-2, which lacks the serine protease domain and a major part of the A chain. Skjoedt et al., Immunobiology, 215:921-31 (2010). Recently, a third member of the family, MASP-3 was identified, which shares a high degree of homology with MASP-1, such that it appears that MASP-1 and MASP-3 are generated as a result of alternative splicing of primary mRNA transcripts.
- MBL/MASP complex and their use for inhibiting the adverse effects of complement activation, such as ischemia-reperfusion injury, have been disclosed, for example, in WO04/075837; US 2009/0017031.
- MBL/Ficolin Associated Protein (MAP- 1), which is present in low serum levels compared to MASP-1 and MASP-3, has been reported to function as a local lectin pathway specific complement inhibitor. Skjodt et al., Molecular Immunology, 47:2229-30 (2010). Accordingly, MAP-1 itself, or fragments of MAP-1, may be useful in the present invention as an inhibitor of MASP, and accordingly, as a lectin-pathway- specific inhibitor of complement activation.
- the ficolin family of proteins are characterized by carbohydrate binding and opsonic activities, sharing a structure similar to MBL. Like MBL, the ficolins have been shown to associate with MASPs in serum and may mediate complement activation in response to
- inhibitors of the ficolin family or functional fragments therof may be useful in the present invention as an inhibitor of MASPs and as a lectin-pathway specific inhibitor of complement activation.
- the inhibitor portion comprises an antibody (or antigen binding fragment thereof) that specifically binds to a human complement component protein (e.g., human C5, C6, C7, C8, or C9).
- a human complement component protein e.g., human C5, C6, C7, C8, or C9.
- the terms "specific binding” or “specifically binds” refer to two molecules forming a complex (e.g., a complex between an antibody and a complement component protein) that is relatively stable under physiologic conditions. Typically, binding is considered specific when the association constant (Ka) is higher than 106 M-l.
- an antibody can specifically bind to a C5 protein with a Ka of at least (or greater than) 106 (e.g., at least or greater than 107, 108, 109, 1010, 1011, 1012, 1013, 1014, or 1015 or higher) M-l.
- Ka of at least (or greater than) 106
- M-l M-l.
- Examples of antibodies that specifically bind to a human complement component C5 protein are described in, e.g., U.S. patent no. 6,355,245 and PCT application publication no. WO 2010/015608.
- Methods for determining whether an antibody binds to a protein antigen and/or the affinity for an antibody to a protein antigen are known in the art and described herein.
- the binding of an antibody to a protein antigen can be detected and/or quantified using a variety of techniques such as, but not limited to, Western blot, dot blot, surface plasmon resonance method (e.g., BIAcore system; Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.), or enzyme-linked immunosorbent assay (ELISA) assays.
- Western blot e.g., BIAcore system; Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.
- ELISA enzyme-linked immunosorbent assay
- the targeted molecule also includes an amino acid linker sequence linking the targeting portion and the inhibitor portion.
- the CR2 portion and the inhibitor portion are non- covalently linked.
- the two portions may be brought together by two interacting bridging proteins (such as biotin and streptavidin), each linked to a CR2 portion or the inhibitor portion.
- the molecule described herein thus generally has the dual functions of binding to a CR2 ligand and inhibiting complement activation of the alternative pathway.
- CR2 ligand refers to any molecule that binds to a naturally occurring CR2 protein, which include, but are not limited to, C3d, iC3b, C3dg, C3d, and cell-bound fragments of C3b that bind to the two N-terminal SCR domains of CR2.
- the CR2-FH molecule may, for example, bind to a CR2 ligand with a binding affinity that is about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the CR2 protein.
- Binding affinity can be determined by any method known in the art, including for example, surface plasmon resonance, calorimetry titration, ELISA, and flow cytometry.
- the molecule has one or more of the following properties of CR2: (1) binding to C3d, (2) binding to iC3b, (3) binding to C3dg, (4) binding to cell-bound fragment(s) of C3b that bind to the two N-terminal SCR domains of CR2.
- the molecule described herein is generally capable of inhibiting complement activation of complement activation (for example the alternative pathway, classical pathway, and/or lectin pathway).
- the molecule may be a more potent complement inhibitor than the naturally occurring inhibitor protein.
- the molecule has a complement inhibitory activity that is about any of 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 40, or more fold of that of the inhibitor protein.
- the molecule has an EC50 of less than about any of 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, or 10 nM.
- the molecule has an EC50 of about 5-60 nM, including for example any of 8-50 nM, 8-20 nM, 10-40 nM, and 20-30 nM. In some embodiments, the molecule has complement inhibitory activity that is about any of 50%, 60%, 70%, 80%, 90%, or 100% of that of the inhibitor protein.
- Complement inhibition can be evaluated based on any methods known in the art, including for example, in vitro zymosan assays, assays for lysis of erythrocytes, antibody or immune complex activation assays, alternative pathway activation assays, classical pathway activation assays and mannan (lectin pathway) activation assays.
- the molecule is a fusion protein.
- the CR2 portion and the inhibitor portion are directly fused to each other.
- the CR2 portion and the inhibitor portion are linked by an amino acid linker sequence.
- Linking sequences can also comprise "natural" linking sequences found between different domains of complement factors.
- VSVFPLE the linking sequence between the first two N-terminal short consensus repeat domains of human CR2
- EEIF the linking sequence between the fourth and the fifth N-terminal short consensus repeat domains of human CR2
- the order of CR2 portion and inhibitor portion in the fusion protein can vary.
- the C-terminus of the CR2 portion is fused (directly or indirectly) to the N-terminus of the inhibitor portion of the molecule.
- the N-terminus of the CR2 portion is fused (directly or indirectly) to the C- terminus of the inhibitor portion of the molecule.
- the molecule is a CR2-FH fusion protein.
- the molecule is a fusion protein.
- Fusion protein used herein refers to two or more peptides, polypeptides, or proteins operably linked to each other.
- the targeting portion and inhibitor portion are directly fused to each other.
- the targeting portion and inhibitor portion are linked by an amino acid linker sequence.
- linker sequences are known in the art, and include, for example, (Gly4Ser), (Gly4Ser)2, (Gly4Ser)3, (Gly3Ser)4, (SerGly4), (SerGly4)2, (SerGly4)3, and (SerGly4)4.
- Linking sequences can also comprise "natural" linking sequences found between different domains of complement factors.
- the order of targeting portion and inhibitor portion in the fusion protein can vary.
- the C-terminus of the targeting portion is fused (directly or indirectly) to the N-terminus of the inhibitor portion of the targeting construct.
- the N-terminus of the targeting portion is fused (directly or indirectly) to the C-terminus of the inhibitor portion of the molecule.
- the molecule comprises a CR2 portion and an inhibitor portion linked via a chemical cross-linker.
- Linking of the two portions can occur on reactive groups located on the two portions.
- Reactive groups that can be targeted using a crosslinker include primary amines, sulfhydryls, carbonyls, carbohydrates, and carboxylic acids, or active groups that can be added to proteins.
- chemical linkers include, but are not limited to, bismaleimidohexane, maleimidobenzoyl-N-hydroxysuccinimide ester, NHS-Esters-Maleimide crosslinkers such as SPDP, carbodiimide, glutaraldehyde, MBS, sulfo-MBS, SMPB, sulfo-SMPB,
- GMBS sulfo-GMBS
- EMCS sulfo-EMCS
- imidoester crosslinkers such as DMA, DMP, DMS, DTBP, EDC and DTME.
- the CR2 portion and the inhibitor portion are non- covalently linked.
- the two portions may be brought together by two interacting bridging proteins (such as biotin and streptavidin), each linked to a CR2 portion or an inhibitor portion.
- the molecule comprises two or more (same or different) CR2 portions described herein.
- the molecule comprises two or more (same or different) inhibitor portions described herein. These two or more CR2 (or inhibitor) portions may be tandemly linked (such as fused) to each other.
- the molecule (such a CR2 -inhibitor fusion protein) comprises a CR2 portion and two or more (such as three, four, five, or more) inhibitor portions. In some embodiments, the molecule (such a CR2 -inhibitor fusion protein) comprises an inhibitor portion and two or more (such as three, four, five, or more) CR2 portions. In some embodiments, the molecule (such a CR2 -inhibitor fusion protein) comprises two or more CR2 portions and two or more inhibitor portions.
- an isolated molecule In some embodiments, there is provided an isolated molecule. In some embodiments, the molecules form dimers or multimers.
- the CR2 portion and the inhibitor portion in the molecule can be from the same species (such as human or mouse), or from different species.
- the CR2-inhibitor molecule comprises CR2Crry comprising the amino acid sequence of SEQ ID NO: 18.
- An exemplary nucleotide sequence encoding CR2Crry is provided in SEQ ID NO: 17.
- the CR2-inhibitor molecule comprises a homolog or biologically active fragment of
- CR2Crry Homologs of the CR2Crry include proteins which differ from CR2Crry described herein (or biologically-active fragment thereof) in that at least one or a few, but not limited to one or a few, amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide or fragment), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition glycosylphosphatidyl inositol).
- a truncated version of the protein such as a peptide or fragment
- derivatized e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition glycosylphosphatidyl inosito
- homologue of CR2Crry may have an amino acid sequence that is at least about 70% identical to the amino acid sequence CR2Crry (e.g., SEQ ID NO: 18), for example at least about any of 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of CR2Crry (e.g., SEQ ID NO: 18).
- Amino acid sequence identity can be determined in various ways, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGNTM (DNAST AR) software.
- BLAST BLAST-2
- ALIGN ALIGN
- MEGALIGNTM DNAST AR
- the CR2-inhibitor molecule comprises human CR2- FH comprising the amino acid sequence of SEQ ID NO: 2.
- the CR2- inhibitor molecule comprises a homolog or biologically active fragment of human CR2- FH.
- Homologs of human CR2-FH include proteins which differ from human CR2-FH described herein (or biologically-active fragment thereof) in that at least one or a few, but not limited to one or a few, amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide or fragment), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition glycosylphosphatidyl inositol).
- homologue of human CR2-FH may have an amino acid sequence that is at least about 70% identical to the amino acid sequence human CR2-FH (e.g., SEQ ID NO: 2), for example at least about any of 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%,
- amino acid sequence identity can be determined in various ways, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or
- MEGALIGNTM DNAST AR
- the CR2-inhibitor molecule comprises mouse CR2- FH comprising the amino acid sequence of SEQ ID NO: 4.
- the CR2- inhibitor molecule comprises a homolog or biologically active fragment of mouse CR2- FH.
- Homologs of mouse CR2-FH include proteins which differ from mouse CR2-FH described herein (or biologically-active fragment thereof) in that at least one or a few, but not limited to one or a few, amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide or fragment), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition glycosylphosphatidyl inositol).
- homologue of mouse CR2-FH may have an amino acid sequence that is at least about 70% identical to the amino acid sequence mouse CR2-FH (e.g., SEQ ID NO: 4), for example at least about any of 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of mouse CR2-FH (e.g., SEQ ID NO: 4).
- Amino acid sequence identity can be determined in various ways, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or
- MEGALIGNTM DNAST AR
- the CR2-inhibitor molecules (or the two portions of the CR2 -inhibitor molecules) described herein may be made by chemical synthesis methods, or by linkage of a polynucleotide encoding the CR2 portion and a polynucleotide encoding the inhibitor portion (with or without a linker sequence), and introducing the resulting polynucleotide molecule in a vector for transfecting host cells that are capable of expressing the molecule. Chemical synthesis, especially solid phase synthesis, is preferred for short peptides or those containing unnatural or unusual amino acids such as D-Tyr, Ornithine, and the like. Recombinant procedures are preferred for longer polypeptides.
- the molecule can be isolated in vitro by protein purification methods.
- the molecule can also be provided "in situ" by introduction of a gene therapy system to the tissue of interest which then expresses the CR2-inhibitor fusion.
- Recombinant DNA techniques for making a CR2-inhibitor fusion protein involves, in simplified form, taking the a CR2-inhibitor encoding polynucleotide, inserting it into an appropriate vector, inserting the vector into an appropriate host cell, and recovering or isolating the fusion protein produced thereby.
- polynucleotides that encode a CR2-inhibitor molecule
- a CR2-inhibitor fusion protein Such polynucleotide may also be used for delivery and expression of CR2-inhibitor.
- a polynucleotide encoding a fusion protein comprising a CR2 portion comprising a CR2 or a fragment thereof and an inhibitor portion comprising an intact inhibitor molecule or a fragment thereof.
- the polynucleotide also comprises a sequence encoding a signal peptide operably linked at the 5' end of the sequence encoding the CR2 -inhibitor fusion protein.
- a linker sequence is used for linking the CR2 portion and the inhibitor portion.
- the polynucleotide encodes a CR2 -inhibitor fusion protein.
- expression vectors comprising a polynucleotide described herein for expression of the CR2-inhibitor fusion protein.
- the expression vector can be used to direct expression of a CR2 -inhibitor fusion protein in vitro or in vivo.
- the vector may include any element to establish a conventional function of a vector, for example, promoter, terminator, selection marker, and origin of replication.
- the promoter can be constitutive or regulative, and is selected from, for example, promoters of genes for galactokinase (GALl), uridylyltransferase (GALT), epimerase (GAL 10), phosphoglycerate kinase (PGK), glyceraldehydes-3 -phosphate dehydrogenase (GPD), alcohol dehydrogenase (ADH), and the like.
- GALl galactokinase
- GALT uridylyltransferase
- GAL 10 epimerase
- PGK phosphoglycerate kinase
- GPD glyceraldehydes-3 -phosphate dehydrogenase
- ADH alcohol dehydrogenase
- E. coli may be transformed using pBR322, a plasmid derived from an E. coli species (Mandel et al., J. Mol. Biol., 53 : 154 (1970)). Plasmid pBR322 contains genes for ampicillin and tetracycline resistance, and thus provides easy means for selection. Other vectors include different features such as different promoters, which are often important in expression.
- plasmids pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden), pKK233-2 (Clontech, Palo Alto, Calif, USA), and pGEMl (Promega Biotech, Madison, Wis., USA), are all commercially available.
- Other vectors that can be used in the present invention include, but are not limited to, pET21a (Studier et al., Methods Enzymol., 185: 60-89 (1990)), pRlT5, and pRlT2T (Pharmacia Biotechnology), and pB0475 (Cunningham et al., Science, 243 : 1330-1336 (1989); U.S. Pat. No.
- Mammalian expression vectors may contain non-transcribed elements such as an origin of replication, promoter and enhancer, and 5' or 3' nontranslated sequences such as ribosome binding sites, a polyadenylation site, acceptor site and splice donor, and transcriptional termination sequences.
- Promoters for use in mammalian expression vectors usually are for example viral promoters such as Polyoma, Adenovirus, HTLV, Simian Virus 40 (SV 40), and human cytomegalovirus (CMV).
- Vectors can also be constructed using standard techniques by combining the relevant traits of the vectors described above.
- host cells such as isolated cells, transient cell lines, and stable cell lines for expressing a CR2-inhibitor fusion protein.
- the host cell may be prokaryotic or eukaryotes.
- Exemplary prokaryote host cells include E. coli K12 strain 294 (ATCC No. 31446), E. coli B, E. coli XI 776 (ATCC No. 31537), E. coli W3110 (F-, gamma-, prototrophic/ ATCC No. 27325), bacilli such as Bacillus subtilis, and other enterobacteriaceae such as Salmonella typhimurium or Serratia marcesans, and various Pseudomonas species.
- E. coli BL21 (Stratagene), which is deficient in the OmpT and Lon proteases, which may interfere with isolation of intact recombinant proteins, and useful with T7 promoter-driven vectors, such as the pET vectors.
- Another suitable prokaryote is E. coli W3110 (ATCC No. 27325).
- the peptides When expressed by prokaryotes the peptides typically contain an N-terminal methionine or a formyl methionine and are not glycosylated. In the case of fusion proteins, the N-terminal methionine or formyl methionine resides on the amino terminus of the fusion protein or the signal sequence of the fusion protein.
- eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for fusion-protein-encoding vectors.
- Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism.
- Others include Schizosaccharomyces pombe (Beach and Nurse, Nature, 290: 140 (1981); EP 139,383 published 2 May 1985); Kluyveromyces hosts (U.S. Pat. No. 4,943,529; Fleer et al., Bio/Technology, 9:968-975 (1991)) such as, e.g., K.
- lactis (MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacterid., 154(2): 737-742 (1983)), K. fragilis (ATCC 12,424), K. bulgaricus (ATCC No. 16,045), K. wickeramii (ATCC No. 24,178), K. waltii (ATCC No. 56,500), K. drosophilarum (ATCC No. 36,906; Van den Berg et al., Bio/Technology, 8: 135 (1990)), K. thermotolerans, and K.
- Aspergillus hosts such as A. nidulans (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 (1983); Tilburn et al., Gene, 26:205-221 (1983); Yelton et al., Proc. Natl. Acad. Sci. USA, 81 : 1470-1474 (1984)) and A. niger (Kelly and Hynes, EMBO J., 4:475- 479 (1985)).
- Methyl otropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula.
- yeast capable of growth on methanol selected from the genera consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula.
- Host cells also include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells.
- Examples of useful mammalian host cell lines include, but are not limited to, HeLa, Chinese hamster ovary (CHO), COS-7, L cells, C127, 3T3, BHK, CHL-1, NSO, HEK293, WI38, BHK, C127 or MDCK cell lines.
- Another exemplary mammalian cell line is CHL-1.
- CHL-1 cells are derived from RPMI 7032 melanoma cells, a readily available human cell line. Cells suitable for use in this invention are commercially available from the ATCC.
- the host cell is a non-human host cell. In some embodiment, the host cell is a CHO cell. In some embodiments, the host cell is a 293 cell.
- the CR2-inhibitor molecules can be isolated by a variety of methods known in the art. In some embodiments, when the CR2-inhibitor molecule is a fusion protein secreted into the growth media, the molecule can be purified directly from the media. If the fusion protein is not secreted, it is isolated from cell lysates. Cell disruption can be done by any conventional method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. The CR2 -inhibitor molecules can be obtained by various methods.
- the CR2-inhibitor molecule can be purified by immunoaffinity chromatography using an antibody that recognizes the CR2 portion or an antibody that recognizes the inhibitor portion, or both.
- an antibody recognizing the first two N-terminal SCR domains of CR2 is used for purifying the CR2- inhibitor molecule.
- the CR2 -inhibitor molecule is purified by ion change chromatography.
- the peptide may or may not be properly folded when expressed as a fusion protein. These factors determine whether the fusion protein must be denatured and refolded, and if so, whether these procedures are employed before or after cleavage.
- a chaotrope such as a guanidine HC1
- a redox buffer containing, for example, reduced and oxidized dithiothreitol or glutathione at the appropriate ratios, pH, and temperature, such that the peptide is refolded to its native structure.
- the CR2-inhibitor molecules described herein may also contain a tag (such as a cleavable tag) for purification.
- a tag such as a cleavable tag
- This tag can be fused to the C-terminus or N- terminus of the CR2 portion or the inhibitor portion, and can be used to facilitate protein purification.
- the CR2 -inhibitor molecule could be synthesized de novo in whole or in part, using chemical methods well known in the art.
- the component amino acid sequences can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid
- composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing.
- the CR2-inhibitor molecules can be assayed for their desired properties using in vitro or in vivo assays. For example, binding of CR2-inhibitor to CR2 ligand can be determined by surface plasmon resonance method.
- surface plasmon resonance method By way of example, kinetic analysis of the interaction of the molecule with C3dg-biotin can be performed using surface plasmon resonance (SPR) measurements made on a BIAcore 3000 instrument (Biacore AB, Uppsala, Sweden).
- SPR surface plasmon resonance
- Human C3dg-biotin can be bound to the surface of BIAcore streptavidin sensor chips by injecting C3dg-biotin over the surface of one flow cell of the chip.
- Binding can be evaluated over a range of CR2-inhibitor molecule concentrations. Association of molecule with the ligand can be monitored for a certain period of time (such as 120 seconds), after which the complex is allowed to dissociate in the presence of buffer only for an additional period of time (such as 120 seconds).
- Binding of CR2 fusion protein fragments to C3dg-immobilized flow cells can be corrected for binding to control flow cells.
- Binding data can be fitted to a 1 : 1 Langmuir binding model using BIAevaluation Version 3.1 software (BIAcore) and evaluated for best fit.
- the kinetic dissociation profiles obtained can be used to calculate on and off rates (ka and kd) and affinity constants (KD) using the BIAevaluation Version 3.1 program.
- Other assay methods for ligand binding are known in the art and can also be used.
- In vitro zymosan complement assay can be used to determine complement inhibitory activity of CR2-inhibitor molecules. Lysis of rabbit erythrocytes by serum in Mg-EGTA is another measure of activity that can be used. Lysis in Mg-EGTA of human or sheep erythrocytes that have had sialic acid removed provides for additional measures of activity.
- the present invention relates to a composition
- a composition comprising an immunosuppressant agent in combination with a CR2-inhibitor molecule.
- the composition comprises a sub-therapeutic amount of an immunosuppressant agent in combination with a CR2-inhibitor molecule.
- the immunosuppressant agent in combination with a CR2-inhibitor molecule.
- the immunosuppressant agent is selected from a list comprising but not limited to cyclosporine A, azathioprine, corticosteroids including prednisone, and methylprednisolone, cyclophosphamide, FK506 and mTOR inhibitors including rapamycin, sirolimus, and everolimus.
- the immunosuppressant agent is cyclosporine A which is an immunosuppressant drug widely used in organ transplantation to
- the immunosuppressant agent is azathioprine, which is an immunosuppressive drug used in organ transplantation and autoimmune diseases and belongs to the chemical class of purine analogues.
- Azathioprine is an imidazolyl derivative and prodrug of mercaptopurine.
- the metabolites of mercaptopurine are incorporated into replicating DNA, halting replication, as well as blocking the pathway for purine synthesis. It thus most strongly affects proliferating cells, such as the T cells and B cells of the immune system.
- the immunosuppressant agent is prednisone which is a synthetic corticosteroid drug that is used to treat certain inflammatory
- the immunosuppressant agent is methylprednisolone which is a synthetic glucocorticoid or corticosteroid drug. It is a variant of prednisolone, methylated at carbon 6 of the B ring.
- the immunosuppressant agent is cyclophosphamide which is an alkylating agent of the nitrogen mustard type (specifically, the
- Cyclophosphamide is used to treat cancers, autoimmune disorders and AL amyloidosis. As a prodrug, it is converted by liver cytochrome P450 (CYP) enzymes to form the metabolite 4-hydroxy cyclophosphamide that has
- the immunosuppressant agent is FK506 is an immunosuppressive drug used mainly after allogeneic organ transplant to lower the risk of organ rejection. It achieves this by inhibiting the production of interleukin-2, a molecule that promotes the development and proliferation of T cells.
- the immunosuppressant agent is an inhibitor of mTOR selected from a group comprising rapamycin, sirolimus, and everolimus.
- the present invention provides methods for enhancing survival of transplant tissue.
- the method comprises administering a composition comprising a CR2-inhibitor molecule to a subject who is the recipient of a transplant tissue.
- the method comprises administering a composition
- the method comprises administering a composition comprising a CR2-inhibitor molecule to a subject before the subject has received the transplant tissue.
- the method comprises administering a composition comprising a CR2-inhibitor molecule to a subject after the subject has received the transplant tissue.
- the method comprises administering a composition comprising a CR2 -inhibitor molecule to transplant tissue ex vivo, prior to introducing the transplant tissue into a recipient subject.
- the method comprises administering a composition comprising a CR2 -inhibitor molecule to a donor subject, prior to harvesting of the transplant tissue.
- the method comprises administering a composition comprising a CR2 -inhibitor molecule in combination with an immunosuppressant agent to a subject or tissue. In one embodiment, the method comprises administering a composition comprising a CR2-inhibitor molecule in combination with a sub-therapeutic level of an immunosuppressant agent to a subject or tissue. In one embodiment, the immunosuppressant agent is selected from a list comprising but not limited to
- cyclosporine A azathioprine
- corticosteroids including prednisone
- methylprednisolone cyclophosphamide
- FK506 cyclophosphamide
- mTOR inhibitors including rapamycin, sirolimus, and everolimus.
- the composition comprises an amount of the immunosuppressant agent that is less than the amount necessary when the
- the amount or concentration of immunosuppressant agent, when administered in combination with a targeted complement inhibitor described herein, is about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of the amount or
- the transplant graft is obtained and modified ex vivo, using the CR2-inhibitor and immunosuppressant agent composition described herein.
- the transplant graft is obtained from a recipient, treated with the composition, and is then placed in contact or in the vicinity of the recipient.
- the transplant graft is placed in a container comprising a suitable media and a composition comprising CR2-inhibitor molecules and immunosuppressant agent, or variant thereof.
- the transplant graft is perfused with a suitable media and a composition comprising CR2 -inhibitor molecules and immunosuppressant agent, or variant thereof.
- the composition comprising CR2 -inhibitor and sub-therapeutic immunosuppressant agent or variant thereof is administered to the transplant graft following removal or harvest of the graft from a donor.
- the composition is administered to the transplant graft less than 72 hours, 48 hours, 36 hours, 24 hours, 18 hours, 12 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 45 minutes, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or 1 minute following removal or harvest of the graft from a donor.
- the composition is administered to the transplant graft for more than 72 hours, 48 hours, 36 hours, 24 hours, 18 hours, 12 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 45 minutes, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or 1 minute prior to transplantation of the transplant graft into the recipient.
- the CR2-inhibitor molecules described herein can function to specifically inhibit in vivo complement activation in the alternative complement pathway and inflammatory manifestations that accompany it, such as recruitment and activation of macrophages, neutrophils, platelets, and mast cells, edema, tissue damage, and direct activation of local and endogenous cells.
- Compositions comprising these molecules can therefore be used for treatment of diseases or conditions that are mediated by excessive or uncontrolled activation of the complement system, particularly diseases or conditions mediated by excessive or uncontrolled activation of the alternative complement pathway.
- methods of treating diseases associated with FH deficiencies for example a decrease in FH level, decrease in FH activity, or lack of wild type or protective FH
- FH FH deficiencies
- a method of treating a disease in which the alternative complement pathway is implicated in an individual comprising administering to the individual an effective amount of a composition comprising a CR2- inhibitor molecule comprising: a) a CR2 portion comprising a CR2 or a fragment thereof, and b) an inhibitor portion comprising an inhibitor (for example a FH molecule) or a fragment thereof.
- a method of inhibiting complement activation in an individual having a disease in which the alternative complement pathway is implicated comprising administering to the individual an effective amount of a composition comprising a CR2 -inhibitor molecule comprising: a) a CR2 portion comprising a CR2 or a fragment thereof, and b) an inhibitor portion comprising an inhibitor molecule or a fragment thereof.
- a method of inhibiting inflammation in an individual having a disease in which the alternative pathway is implicated comprising administering to the individual an effective amount of a composition comprising a CR2 -inhibitor molecule comprising: a) a CR2 portion comprising a CR2 or a fragment thereof, and b) an inhibitor portion comprising an inhibitor or a fragment thereof.
- the disease to be treated is ischemia reperfusion.
- Ischemia reperfusion (I/R) injury refers to inflammatory injury to the endothelium and underlying parenchymal tissues following reperfusion of hypoxic tissues. Ischemia reperfusion injury can result in necrosis and irreversible cell injury.
- the complement pathway (including the alternative complement pathway) is a major mediator of I/R injury. Methods provided herein are thus useful for treatment of ischemia reperfusion that occurs in any organ or tissues, such as ischemia-reperfusion injury of any transplanted organ or tissue. Other conditions and diseases in which ischemia-reperfusion injury occurs will be known to those of skill in the art.
- the present invention provides, methods of treating and/or preventing graft rejection with provided compositions.
- graft rejection may be autograft rejection, xenograft rejection, and/or allograft rejection.
- the present invention provides methods of treating and/or preventing graft-versus-host disease.
- organ transplantation For dysfunctional, diseased, and/or otherwise undesired tissues or organs of the body, besides therapeutic intervention with drugs, organ and/or tissue transplantation is an alternative, and, in some cases, the last resort in the treatment of a patient. Particularly for patients with leukemia, end-stage renal, cardiac, pulmonary or hepatic failure, organ transplantation is quite commonly used in the treatment.
- allografts organ grafts harvested from donors other than the patient him/herself or host/recipient of the graft
- allografts of various types, e.g. kidney, heart, lung, liver, bone marrow, pancreas, cornea, small intestine and skin (e.g. epidermal sheets)
- xenografts organ grafts harvested from non-human animals, such as porcine heart valves, may be used to replace their dysfunctional human counterparts.
- tissue transplantation is or comprises bone marrow and/or stem cell transplantation.
- Bone marrow and/or stem cell transplantation has applications in a wide variety of clinical settings, including solid organ transplantation.
- a major goal in solid organ transplantation is the engraftment of the donor organ without a graft rejection immune response generated by the recipient, while preserving the immune-competence of the recipient against other foreign antigens.
- nonspecific immunosuppressive agents such as cyclosporin A, azathioprine, corticosteroids including prednisone, and methylprednisolone, cyclophosphamide, and FK506 are used.
- nonspecific immunosuppressive agents function by suppressing all aspects of the immune response, thereby greatly increasing a recipient's susceptibility to infections and diseases, including cancer. Accordingly, using the herein defined composition comprising a complement-targeted inhibitor in combination with a subtherapeutic dose of an immunotherapeutic agent, and more safe and efficacious treatment plan is made herein available.
- tissue transplantation is or comprises hematopoietic tissue transplantation (e.g. bone marrow transplantation).
- hematopoietic tissue transplantation e.g. bone marrow transplantation
- a goal of hematopoietic tissue transplantation is to achieve the successful engraftment of donor cells within a recipient host, such that immune and/or hematopoietic chimerism results.
- Chimerism is the reconstitution of the various compartments of the recipient's hematoimmune system with donor cell populations bearing MHC molecules derived from both, the allogeneic or xenogeneic donor, and a cell population derived from the recipient or, alternatively, the recipient's hematoimmune system compartments which can be reconstituted with a cell population bearing MHC molecules derived from only the allogeneic or xenogeneic marrow donor.
- Chimerism may vary from 100% (total replacement by allogenic or xenogeneic cells) to low levels detectable only by molecular methods. Chimerism levels may vary over time and be permanent or temporary.
- graft rejection refers to an autograft rejection, wherein the donor individual and recipient individual are the same (i.e., a patient's own tissue).
- the present invention provides, among other things, methods of administering to a recipient organism who has received or will receive a transplant of one or more heterologous tissue components from a donor organism, a composition comprising encapsulated recipient organism tissue components.
- one or more recipient tissue components are encapsulated within a nanoparticle. In some embodiments, one or more recipient tissue components are encapsulated within a microbial cell. In some embodiments, one or more provided compositions are administered prior to the transplant. In some embodiments, one or more provided compositions are administered subsequent to the transplant.
- graft rejection refers to a xenograft rejection, wherein the donor and recipient are of different species.
- xenograft rejection occurs when the donor species tissue carries a xenoantigen against which the recipient species immune system mounts a rejection response.
- the present invention provides, among other things, methods of administering to a recipient organism who has received or will receive a transplant of one or more heterologous tissue components from a donor organism of different species a composition comprising encapsulated donor organism tissue components.
- a composition comprising encapsulated donor organism tissue components.
- donor porcine tissue components are isolated, encapsulated within nanoparticles, and administered to a recipient organism. Allograft Rejection
- graft rejection refers to an allograft rejection, wherein the donor individual and recipient individual are of the same species.
- allograft rejection occurs when the donor tissue carries an alloantigen against which the recipient immune system mounts a rejection response.
- the present invention provides, among other things, methods of administering to a recipient organism who has received or will receive a transplant of one or more heterologous tissue components from a donor organism a composition comprising encapsulated donor organism tissue components.
- one or more heterologous tissue components are encapsulated within a nanoparticle. In some embodiments, one or more heterologous tissue components are encapsulated within a microbial cell. In some embodiments, one or more heterologous tissue components are from a different species. In some embodiments, one or more provided compositions are administered prior to the transplant. In some embodiments, one or more provided compositions are administered subsequent to the transplant.
- provided formulations may be used to treat patients with various forms of GvHD including acute and chronic GvHD that is either naive or refractory to conventional immunosuppressive agents such as steroids and cyclosporine A.
- provided formulations may be used as prophylaxis to prevent onset of GvHD by pretreating (i.e., tolerizing) the transplant recipient (i.e. host) prior to the transplantation and/or treating the recipient (i.e., host) within a certain time window post transplantation.
- provided formulations may be used to treat patients with various forms of GvHD.
- the host e.g., transplant recipient
- the host is treated with one or more compositions comprises herein after receiving one or more tissue transplantation (i.e., tissue graft, organ transplant, etc.).
- tissue transplantation i.e., tissue graft, organ transplant, etc.
- compositions described herein can be administered to an individual via any route, including, but not limited to, intravenous (e.g., by infusion pumps), intraperitoneal, intraocular, intra-arterial, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intrathecal, transdermal, transpleural, topical, inhalational (e.g., as mists of sprays), mucosal (such as via nasal mucosa),
- compositions are administered systemically (for example by intravenous injection). In some embodiments, the compositions are administered locally (for example by intraarterial or intraocular injection). In some embodiments, the compositions are administered by ex vivo incubation or perfusion.
- provided pharmaceutical formulations are administered to a subject in combination with one or more other therapeutic agents or modalities, for example, useful in the treatment of one or more diseases, disorders, or conditions treated by the relevant provided pharmaceutical formulation, so the subject is simultaneously exposed to both.
- a provided tissue component composition is utilized in a pharmaceutical formulation that is separate from and distinct from the pharmaceutical formulation containing the other therapeutic agent.
- a provided tissue component composition is admixed with the composition comprising the other therapeutic agent.
- a provided tissue component composition is produced individually, and the provided tissue component composition is simply mixed with another composition comprising another therapeutic agent.
- provided formulations can be administered concurrently with, prior to, or subsequent to, one or more other therapeutic agents (e.g., desired known
- the therapies employed may achieve a desired effect for the same disorder (for example, a provided tissue component composition useful for treating transplant rejection may be administered concurrently with a known immunosuppressant therapeutic that is also useful for treating transplant rejection), or they may achieve different effects (for example, a provided tissue component composition that is useful for treating transplant rejection may be
- provided tissue component compositions in accordance with the invention are administered with a second therapeutic agent.
- the terms “in combination with” and “in conjunction with” mean that the provided CR2-inhibitor formulation can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics such as an
- immunosuppressant agent including but not limited to a sub-therapeutic dose of such an immunosuppressant agent.
- each substance will be administered at a dose and/or on a time schedule determined for that agent.
- the method comprises administering a
- composition comprising a combination of an immunosuppressive agent and a CR2- inhibitor described herein.
- the method comprises administering one or more compositions.
- the method comprises administering a first composition comprising an immunosuppressive agent and a second composition comprising a CR2 -inhibitor described herein.
- the different compositions may be administered to the subject in any order and in any suitable interval.
- the one or more compositions are administered simultaneously or near simultaneously.
- the method comprises a staggered administration of the one or more compositions, where a first composition is
- the method has an additive effect, wherein the overall effect of the administering a combination of therapeutic agents or procedures is approximately equal to the sum of the effects of administering each therapeutic agent or procedure alone. In other embodiments, the method has a synergistic effect, wherein the overall effect of administering a combination of therapeutic agents or procedures is greater than the sum of the effects of administering each therapeutic agent or procedure alone.
- the host receives medications, chemotherapy (i.e., destroy host bone marrow), total body irradiation, and other antibody medications before receiving donor tissue transplant.
- chemotherapy i.e., destroy host bone marrow
- total body irradiation i.e., total body irradiation
- other antibody medications before receiving donor tissue transplant.
- chance of graft rejection is related to the match between the donor and host MHC antigens, the overall genetic relationship between donor and host, and the type of disease for which the transplantation has been performed.
- immunosuppressive therapy includes administration of corticosteroids (e.g., prednisolone, hydrocortisone, etc.), calcineurin inhibitors (e.g., cyclosporine, tacrolimus, etc.), anti-proliferatives (e.g., azathioprine, mycophenolic acid, etc.), mTOR inhibitors (e.g., sirolimus, rapamycin, everolimus, etc.), and/or combinations thereof.
- corticosteroids e.g., prednisolone, hydrocortisone, etc.
- calcineurin inhibitors e.g., cyclosporine, tacrolimus, etc.
- anti-proliferatives e.g., azathioprine, mycophenolic acid, etc.
- mTOR inhibitors e.g., sirolimus, rapamycin, everolimus, etc.
- corticosteroids are coadministered with one or more calcineurin inhibitors and one or more anti-proliferative agents.
- mTOR inhibitors are used where calcineurin inhibitors or steroids are contraindicated.
- antibody-based therapy includes administration of one or more antibodies or antibody -based drugs specific to select immune system components (e.g., IL-2R.0C. receptor, CD20, T-cells, etc.).
- Non-limiting examples of antibodies or antibody-based drugs include monoclonal anti-IL-2R. a.
- GvHD graft-versus-host disease
- tissue transplant e.g. tissue implantation, graft, etc.
- GvHD occurs when transplanted donor immune cells (e.g., white blood cells including T cells) present in the graft (i.e. donor) tissue recognize the host (i.e., recipient) as "non-self (i.e., antigenically "foreign") and attack the tissues of the recipient.
- Donor infection-fighting cells attack tissues in the host just as if they were attacking an infection.
- bone marrow transplant presents risk of GvHD, because mature donor lymphocytes present within transplanted donor marrow may recognize recipient tissues as foreign.
- the transplanted donor immune cells then attack the host's body cells and destroy them.
- GvHD is most commonly associated with stem cell or bone marrow transplant, but applies to other forms of tissue graft as well.
- three criteria must be met in order for GvHD to occur.
- an immune-competent graft i.e., donor tissue
- viable and functional donor immune cells i.e., transplanted to host
- the host is immunologically disparate (i.e., histo-incompatible).
- the host is immune- compromised and cannot destroy or inactivate the transplanted donor immune cells.
- lymphocytes i.e., T cells
- TNF-alpha TNF-alpha
- IFNy interferon-gamma
- MHC- identical siblings or MHC-identical unrelated donors often have genetically different proteins (i.e., minor histocompatibility antigens) that can be presented by MHC molecules to the donor's T-cells, which see these antigens as foreign and so mount an immune response.
- minor histocompatibility antigens i.e., minor histocompatibility antigens
- donor T-cells are undesirable as effector cells of GvHD, they are valuable for engraftment by preventing the host residual immune system from rejecting the bone marrow graft (i.e., host-versus-graft; discussed above).
- GvHD is either acute GvHD (aGVHD) or chronic
- GvHD cGVHD
- Acute GvHD usually occurs within the first three months following a transplant, and can affect the skin, liver, stomach, and/or intestines.
- symptoms of aGvHD include rash, yellow skin and eyes due to elevated concentrations of bilirubin, and diarrhea.
- Acute GvHD is graded on a scale of 1 to 4; grade 4 is the most severe. In some embodiments, aGvHD can be fatal.
- Chronic GvHD (cGvHD) is the late form of the disease, and usually develops three months or more after a transplant.
- the symptoms of cGvHD resemble spontaneously occurring autoimmune disorders such as lupus or scleroderma.
- GvHD is more easily prevented than treated.
- Preventive measures include the administration of cyclosporin with or without methotrexate or steroids after stem cell transplant.
- T lymphocytes are removed from the stem cell graft before it is transplanted.
- first-line treatment of GvHD includes steroid therapy.
- chronic GvHD occurs approximately in 10-40 percent of patients after stem cell transplant.
- symptoms vary more widely than those of acute GvHD and are similar to various autoimmune disorders.
- symptoms include dry eyes, dry mouth, rash, ulcers of the skin and mouth, joint contractures (i.e., inability to move joints easily), abnormal blood test results of liver function, stiffening of the lungs (i.e., difficulty in breathing), inflammation in the eyes, difficulty in swallowing, muscle weakness, a white film in the mouth, and/or combinations thereof.
- the incidence of GvHD increases with increasing degree of mismatch between donor and host HLA antigens, increasing donor age and increasing host age.
- compositions comprising a CR2- inhibitor molecule and a pharmaceutically acceptable carrier.
- the pharmaceutical compositions may be suitable for a variety of modes of administration described herein, including for example systemic or localized administration.
- the pharmaceutical compositions can be in the form of eye drops, injectable solutions, or in a form suitable for inhalation (either through the mouth or the nose) or oral administration.
- the pharmaceutical compositions described herein can be packaged in single unit dosages or in multidosage forms.
- the pharmaceutical compositions comprise a pharmaceutically acceptable carrier suitable for administration to human. In some embodiments, the pharmaceutical compositions comprise a pharmaceutically acceptable carrier suitable for intraocular injection. In some embodiments, the pharmaceutical compositions comprise a pharmaceutically acceptable carrier suitable for topical application. In some embodiments, the pharmaceutical compositions comprise a pharmaceutically acceptable carrier suitable for intravenous injection. In some embodiments, the pharmaceutical compositions comprise and a pharmaceutically acceptable carrier suitable for injection into the arteries.
- compositions are generally formulated as sterile, substantially isotonic, and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.
- GMP Good Manufacturing Practice
- the composition is free of pathogen.
- the pharmaceutical composition can be in the form of liquid solutions, for example in physiologically compatible buffers such as Hank's solution or Ringer's solution.
- the CR2- inhibitor pharmaceutical composition can be in a solid form and redissolved or suspended immediately prior to use. Lyophilized compositions are also included.
- the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate).
- binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants e.g., magnesium stearate, talc or silica
- disintegrants e.g., potato star
- Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., ationd oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
- suspending agents e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats
- emulsifying agents e.g., lecithin or acacia
- non-aqueous vehicles e.g., ationd oil, oily esters,
- preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
- compositions comprising a CR2-inhibitor molecule and a pharmaceutically acceptable carrier suitable for administration to the eye.
- pharmaceutical carriers can be sterile liquids, such as water and oil, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and the like.
- Saline solutions and aqueous dextrose, polyethylene glycol (PEG) and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, sodium state, glycerol monostearate, glycerol, propylene, water, and the like.
- the pharmaceutical composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- the CR2 -inhibitor molecule and other components of the composition may be encased in polymers or fibrin glues to provide controlled release of the molecule.
- compositions can take the form of solutions, suspensions, emulsions, ointment, gel, or other solid or semisolid compositions, and the like.
- the compositions typically have a pH in the range of 4.5 to 8.0.
- the compositions must also be formulated to have osmotic values that are compatible with the aqueous humor of the eye and ophthalmic tissues. Such osmotic values will generally be in the range of from about 200 to about 400 milliosmoles per kilogram of water (“mOsm/kg”), but will preferably be about 300 mOsm/kg.
- the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for injection intravenously, intraperitoneally, or intravitreally.
- compositions for injection are solutions in sterile isotonic aqueous buffer.
- the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection.
- the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
- composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
- compositions may further comprise additional ingredients, for example preservatives, buffers, tonicity agents, antioxidants and stabilizers, nonionic wetting or clarifying agents, viscosity-increasing agents, and the like.
- additional ingredients for example preservatives, buffers, tonicity agents, antioxidants and stabilizers, nonionic wetting or clarifying agents, viscosity-increasing agents, and the like.
- Suitable preservatives for use in a solution include polyquaternium-1, benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, benzethonium chloride, and the like.
- such preservatives are employed at a level of from 0.001% to 1.0% by weight.
- Suitable buffers include boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, sodium biphosphate and the like, in amounts sufficient to maintain the pH at between about pH 6 and pH 8, and preferably, between about pH 7 and pH 7.5.
- Suitable tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, sodium chloride, and the like, such that the sodium chloride equivalent of the ophthalmic solution is in the range 0.9 plus or minus 0.2%.
- Suitable antioxidants and stabilizers include sodium bisulfite, sodium metabi sulfite, sodium thiosulfite, thiourea and the like.
- Suitable wetting and clarifying agents include polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol.
- Suitable viscosity-increasing agents include dextran 40, dextran 70, gelatin, glycerin,
- hydroxyethylcellulose hydroxmethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone,
- viscosity enhancing agents to provide topical compositions with viscosities greater than the viscosity of simple aqueous solutions may be desirable.
- viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents know to those skilled in the art. Such agents are typically employed at a level of from 0.01% to 2% by weight.
- a pharmaceutical composition for delivery of a nucleotide encoding a CR2-inhibitor molecule can be in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle or compound is imbedded.
- the pharmaceutical composition can comprise one or more cells which produce the gene delivery system.
- a gene delivery system for a gene therapeutic can be introduced into a subject by any of a number of methods.
- a pharmaceutical composition of the gene delivery system can be introduced systemically, e.g., by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof.
- initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized.
- the gene delivery vehicle can be introduced by catheter, See U.S. Pat. No. 5,328,470, or by stereotactic injection, Chen et al. (1994), Proc.
- a polynucleotide encoding a CR2 -inhibitor molecule can be delivered in a gene therapy construct by electroporation using techniques described, Dev et al. (1994), Cancer Treat. Rev. 20: 105-115.
- compositions can be determined empirically and will depend on the type and severity of the disease, route of administration, and
- the effective amount can also be determined based on in vitro complement activation assays.
- dosages of CR2 -inhibitor molecules which can be used for methods described herein include, but are not limited to, an effective amount within the dosage range of any of about 0.01 mg/kg to about 300 mg/kg, or within about 0.1 mg/kg to about 40 mg/kg, or with about 1 mg/kg to about 20 mg/kg, or within about 1 mg/kg to about 10 mg/kg.
- the amount of CR2-FH administered to an individual is about 10 mg to about 500 mg per dose, including for example any of about 10 mg to about 50 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, about 200 mg to about 300 mg, about 300 mg to about 500 mg, about 500 mg to about 1 mg, about 1 mg to about 10 mg, about 10 mg to about 50 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, about 200 mg to about 300 mg, about 300 mg to about 400 mg, or about 400 mg to about 500 mg per dose.
- the CR2-inhibitor compositions may be administered in a single daily dose, or the total daily dose may be administered in divided dosages of two, three, or four times daily.
- the compositions can also be administered less frequently than daily, for example, six times a week, five times a week, four times a week, three times a week, twice a week, once a week, once every two weeks, once every three weeks, once a month, once every two months, once every three months, or once every six months.
- the compositions may also be administered in a sustained release formulation, such as in an implant which gradually releases the composition for use over a period of time, and which allows for the composition to be administered less frequently, such as once a month, once every 2-6 months, once every year, or even a single administration.
- the sustained release devices (such as pellets, nanoparticles, microparticles, nanospheres, microspheres, and the like) may be administered by injection or surgical implantation in various locations.
- Dosage amounts and frequency will vary according the particular formulation, the dosage form, and individual patient characteristics. Generally speaking, determining the dosage amount and frequency for a particular formulation, dosage form, and individual patient characteristic can be accomplished using conventional dosing studies, coupled with appropriate diagnostics.
- unit dosage forms of CR2- inhibitor molecule compositions each dosage containing from about 0.01 mg to about 50 mg, including for example any of about 0.1 mg to about 50 mg, about 1 mg to about 50 mg, about 5 mg to about 40 mg, about 10 mg to about 20 mg, or about 15 mg of the CR2-inhibitor molecule.
- the unit dosage forms of CR2- inhibitor molecule composition comprise about any of 0.01 mg-0.1 mg, 0.1 mg-0.2 mg, 0.2 mg-0.25 mg, 0.25 mg-0.3 mg, 0.3 mg-0.35 mg, 0.35 mg-0.4 mg, 0.4 mg-0.5 mg, 0.5 mg-1.0 mg, 10 mg-20 mg, 20 mg- 50 mg, 50 mg-80 mg, 80 mg-100 mg, 100 mg-150 mg, 150 mg-200 mg, 200 mg-250 mg, 250 mg-300 mg, 300 mg-400 mg, or 400 mg-500 mg CR2- inhibitor molecule.
- the unit dosage form comprises about 0.25 mg CH2- inhibitor molecule.
- unit dosage form refers to a physically discrete unit suitable as unitary dosages for an individual, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient.
- suitable pharmaceutical carrier diluent, or excipient.
- unit dosage forms can be stored in suitable packaging in single or multiple unit dosages and may also be further sterilized and sealed.
- kits comprising compositions (or unit dosages forms and/or articles of manufacture) described herein and may further comprise instruction(s) on methods of using the composition, such as uses described herein.
- the kits described herein may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for performing any methods described herein.
- Example 1 Targeted complement inhibition protects vascularized composite allografts from acute graft injury and prolongs graft survival when combined with subtherapeutic cyclosporine A therapy.
- mice Male Balb/c (H-2 d ) and C57BL/6 (B6; H-2 b ) mice (10-12 weeks) were obtained from Jackson laboratory (Bar Harbor, ME). Male CSaR ⁇ ' CSaR " " and C3-/- C57BL/6 mice were obtained. All mice weighed 25-30 g and were housed under specific pathogen-free conditions.
- mice were used as donors, and C57B1/6, CSaR ⁇ ' CSaR " " and C3 _/"
- mice were used as recipients.
- a heterotopic hindlimb Tx model was used.
- animals were randomized into four groups: 1. Balb/c donors and wild type (WT) B6 recipients with PBS treatment, 2. Balb/c donors and CSaR ⁇ ' CSaR " " B6 recipients, 3. Balb/c donors and C3 _/" B6 recipients, 4. Balb/c donors and WT B6 recipients administered two doses of 0.25 mg CR2-Crry complement inhibitor immediately upon completion of surgery, and again 24 hours posttransplantation.
- WT wild type
- mice were anesthetized with intraperitoneal injections of ketamine (75 mg/kg) and xylazine (16 mg/kg) diluted in sterile saline, and the cold ischemia time for all grafts was 2 h.
- CR2-Crry was produced and purified as previously described (Atkinson et al., 2005, The Journal of clinical investigation, 115(9): 2444-2453). Dose was based on previously published data (Atkinson et al., 2005, The Journal of clinical investigation, 115(9): 2444-2453, Huang et al., 2008, Journal of immunology, 181(11): 8068-8076). Histopathology
- VCAs were isolated and subsequently placed in 10% buffered formaldehyde solution for 48 hours before being embedded in paraffin.
- Four ⁇ graft sections were stained with Hematoxylin and Eosin (HE) and scored using a semiquantitative histology scoring system as described (Hautz et al., 2014, Transplantation, 98(7): 713-720).
- HE Hematoxylin and Eosin
- Splenocytes were isolated from naive mice, and from mice that had received Balb/c allografts from four groups; 1. B6 recipient, no treatment, 2. B6 recipient, treatment with 3mg/kg/day CsA, 3. B6 recipient, treatment with CR2-Crry, and 4. B6 recipient, treatment with CR2-Crry + 3mg/kg/day CsA. Spleens were isolated 7 days post-transplant and splenocytes isolated and frozen for later analysis.
- splenocytes were stained for cell surface markers (CD3 eFluor450, CXCR3 FITC; eBioscience; CD4 APC Cy7, CD8 APC, CD44 PerCP Cy5.5, CD62L FITC, FoxP3 PE, BD Biosciences) in FACS buffer (PBS + 2% FBS) for 20 minutes at room temperature. Cells were then washed and incubated in Fixation Buffer (BioLegend) for 10 minutes. After washing, cells were run on a BD Verse (BD Biosciences) and analyzed using Flow Jo software (Tree Star, Ashland, OR).
- GraphPad Prism version 5.0 for Mac OS X (GraphPad, San Diego, CA) was used for statistical analysis. A student t test was used for the comparison of a normally distributed continuous variable between two groups. Differences between various groups were compared by the nonparametric Wilcoxon rank-sum or Mann- Whitney test because of the small sample sizes for some experiments. The Mantel Cox text was used to compare survival curves for different groups on univariate analyses. All analyses were 2 sided, and values of P ⁇ 0.05 were considered to be statistically significant.
- Vascularized composite allografts from Balb/c WT donors were transplanted into the following C57BL/6 recipients: 1. WT mice treated with PBS vehicle at 0 and 24 h post-reperfusion; 2. Double CSaR ⁇ VCSaR " " mice; 3. C3 _/” mice; 4. WT mice treated with 0.25 mg CR2-Crry at 0 and 24 hours post-reperfusion. Skin and muscle tissue from allografts was isolated 48 h after Tx and assessed for injury and cellular infiltration. Allografts isolated from PBS treated WT recipients exhibited key features associated with IRI, including epidermal and muscle cell necrosis, and inflammatory cell infiltration of the epidermis localized to areas of muscle necrosis (Figure 1).
- organ IRI The paradigm for organ IRI is that following reperfusion, circulating self- reactive natural IgM Abs bind to ischemia-induced neoepitopes or danger associated molecular patterns (DAMPs) and activate complement (Ioannou et al., 2011, Clinical immunology, 141(1): 3-14). The binding of IgM and deposition of the C3d complement activation product in allografts was then investigated. At 48 h post-transplant, IgM staining was evident in both skin and muscle tissue, with a similar pattern and intensity in allografts from all recipient groups ( Figure 2 A and B).
- C3d deposition was significantly lower in both the skin and muscle of allografts from C3 deficient and CR2-Crry treated recipients when compared to allografts from WT and CSaR ⁇ VCSaR " " mice (donor-derived complement can account for the low levels of C3d deposition observed in allografts from C3-/- recipients). Furthermore, IgM and C3d co-localized in allografts from WT mice, indicating IgM-mediated activation of complement ( Figure 2C). These data indicate sequential IgM binding and complement activation, since neither complement deficiency nor inhibition affected IgM binding. The data further
- the anaphylatoxins in particular C5a, are known to play important roles in the recruitment of immune cells to sites of inflammation, allograft infiltration of neutrophils and macrophages 48 h after Txm, was investigated.
- Immunohistological assessment demonstrated extensive infiltration of both cell types in allografts from control WT recipients. Neutrophils and macrophages were localized to the dermis in the skin and spread between myocytes in muscle tissue. Compared to WT recipients, the number of infiltrating cells was significantly reduced in allografts from CSaR ⁇ VCSaR " " recipients, with the exception of skin neutrophils.
- the adhesion molecule P-selectin is expressed on endothelial cells early after IR, and it is an important mediator of leukocyte infiltration and injury, at least in some organs and tissues. Adhesion molecules also modulate the infiltration of lymphocytes involved in alloimmunity. Moreover, there is a dynamic between P-selectin expression and complement activation (Del Conde et al., 2005, The Journal of experimental medicine, 201(6): 871-879), and therefore the effect of complement deficiency and inhibition on P-selectin expression in VC allografts was investigated.
- CsA Cyclosporine A
- Vascularized composite allograft rejection is primarily dependent on T cells, and demonstrates that complement activation within donor organs contributes to post-transplant ischemic injury and memory T cell infiltration and proliferation. It was then determined how CR2-Crry treatment affected graft rejection and T cell infiltration into allografts when recipients were co-treated with a subtherapeutic 3 mg/kg/day dose of CsA. Graft rejection was evident macroscopically in untreated recipients and in recipients treated with a subtherapeutic dose of CsA alone at day 7 post-transplant (Figure 6A).
- VCA surgical procedures have become highly successful, the high incidence of acute rejection within the first year after surgery (Fischer et al., 2014, Current opinion in organ transplantation, 19(6): 531-544) and the requirement for long- term and high-dose immunosuppression (Fischer et al., 2014, Current opinion in organ transplantation, 19(6): 531-544, Napoli et al., 2012, Neuron, 73(4): 729-742) remain obstacles to its widespread application.
- Current immunosuppression strategies applied in VCA are extrapolated from solid organ Tx regimens (Petruzzo et al., 2010,
- C3aR/C5aR deficiency in the recipient was protective against IRI
- C3 deficiency and C3 inhibition provided significantly better protection in both skin and muscle compartments.
- the anaphylatoxins may contribute to IRI, via the recruitment and/or activation of leukocytes, C3 opsonins and/or the MAC play a prominent role in VCA IRI.
- the MAC appears to be the primary mediator of IRI (Zhang et al., 2011, The American journal of pathology, 179(6): 2876-2884, Turnberg et al., 2004, The American journal of pathology, 165(3): 825-832, Marshall et al., 2014, The Journal of experimental medicine, 211(9): 1793-1805, Austen et al., 1999, Surgery, 126(2): 343-348).
- deposition of the MAC at sublytic concentrations can, as can the anaphylatoxins, result in the activation of endothelial cells and the recruitment and activation of leukocytes (Morgan BP et al., 2015, Immunobiology, 221(6): 747-751, Merle et al., 2015, Frontiers in immunology, 6: 257).
- Activated endothelial cells and recruited macrophages function as APCs, and C3 opsonization can facilitate cell/antigen uptake via complement receptor engagement.
- Complement-dependent injury will also result in the expression of DAMPs, such as heat shock proteins, reactive oxygen species and fibrinogen (Caterson et al., 2013, The Journal of craniofacial surgery.
- the data also demonstrates IgM-mediated activation of complement occurs in composite allografts, and for cardiac grafts it has been demonstrated that DAMPs exposed after transplant are recognized by self-reactive natural IgM Abs that activate complement in the transplanted heart (Atkinson et al., 2015, Circulation, 131(13): 1171-1180).
- the activities of complement activation products provide a basis for how complement may augment graft allogenicity via IRI (Caterson et al., 2013, The Journal of craniofacial surgery. 24(1): 51-56).
- C3a and C5a receptors expressed on APCs and T cells can stimulate differentiation, expansion and survival of effector T cells, and C3a/C5a receptor signaling can also reduce the suppressive activity of regulatory T cells, thus promoting T cell alloimmunity (Kwan et al., 2012, Immunologic research, 54(1-3): 247-253).
- complement activation products C3a, C5a, C3 opsonins, and the MAC have all been implicated in acute graft inflammation and injury following solid organ Tx, and organ IRI is implicated in promoting the development of graft rejection.
- CR2-Crry is a pan-complement inhibitor that inhibits the generation of all of the above complement activation products, and the data shown here demonstrates that a treatment directed at inhibiting complement-mediated IRI of VC allografts is a promising therapeutic strategy.
- CR2-mediated targeting of complement inhibition significantly increases bioavailability and efficacy, and obviates the need for systemic inhibition that reduces any additional immunosuppressive effect, a potentially important consideration when the patient is immune-compromised.
- Example 2 Inhibition of Alternative Complement pathway in Target Organs represents a novel and effective approach to control GVHD while sparing GVL Effect
- Allogeneic hematopoietic stem cell transplantation is an effective immunotherapy for hematological malignancies.
- application of allo- HSCT is limited by graft-versus-host-disease (GVHD), and separation of GVHD and graft-versus-leukemia (GVL) is a great challenge in the field.
- Complement can be activated via three different pathways: classical, lectin and alternative pathway. Owning to the auto-activation property and crucial in "amplification loop", alternative complement pathway (ACP) plays a central role in the development of autoimmune diseases such as colitis and inflammatory bowel disease, which share certain
- CR2-fH consists of the N-terminus of mouse complement factor H, which contains the APC-inhibitory domain, linked to a complement receptor 2 (CR2) targeting fragment that binds complement activation product C3d which highly expressed at GVHD target organs ( Figure 13).
- mice deficient for fB or Clq/MLB were used as recipients in which the ACP or classical/actin pathway is altered.
- MHC-mismatched murine models of GVHD it was determined that GVHD severity and mortality was significantly reduced in fB but not Clq/MLB deficient recipients compared to wild type (WT) counterpart, suggesting a crucial role of ACP in GVHD pathogenesis after allo-HSCT, as shown in Figure 15 A. It has shown that CR2-fH co-localizes with C3d in injured issues.
- donor T cells and particularly CD103+CD8+ T cells were decreased in the gut of fB-/- recipients. Consistently, in the fB-/- recipients, donor T cells reduced the expression of gut homing chemokine CCR9. Donor Thl and Tel cells were significantly decreased whereas donor iTregs were increased in the liver of fB-/- recipients ( Figure 16B). Meanwhile, donor Th2 and Tel were diminished in the lung. The cytolytic activity of liver-infiltrated lymphocyte was also lower in the absence of host ACP. The thymic integrity was significantly improved in fB-/- recipients. No differences in differentiation and function of donor T cells in lymphoid organs were found in the fB-/- recipients ( Figure 16C). These studies suggest that complement activation in target organs is important for GVHD pathogenesis.
- this study identifies a central role of ACP in GVHD and validates ACP as a therapeutic target for the control of GVHD. It provides evidences that locally-generated complement at GVHD target organs is important for GVHD
- Example 3 In vitro characterization of Map44-CR2.
- a construct was designed which includes MAp44 linked to CR2 (MAp44- CR2; SEQ ID NO: 16).
- a binding (targeting) assay is conducted where an ELISA plate coated with C3d or BSA is incubated with various concentrations of MAp44-C4. The plates are then washed and binding is detected by means of anti-Map44 mAb.
- a lectin pathway inhibition assay is conducted using a lectin pathway-specific assay using mannan coated ELISA plates ( Figure 17)
- Example 4 CR2-Crry and subtherapeutic rapamycin therapy.
- rapamycin potent Treg inducing capacity is well documented it is seldom used in clinical Tx due to severe side-effects associated with poor wound healing, patient tolerability issues, infection and cancer.
- a number of novel strategies have been employed in an attempt to utilize rapamycin, one such is the use of rapamycin at subtherapeutic doses combine with ex-vivo expanded Tregs to support therapeutic levels of Treg proliferation in vivo.
- the strategy described herein employs a sub-therapeutic rapamycin dosing strategy, that does not alone protect against AV development, combined with early complement inhibition with CR2-Crry (C3 convertase inhibitor) and anti-C5 (C5 and MAC inhibitor) administered at 0 and 24 hrs post reperfusion.
- CR2-Crry C3 convertase inhibitor
- anti-C5 C5 and MAC inhibitor
- Six groups are utilized, 1. No treatment control, 2. Rapamycin administered at 300ng dose on days 7, 9, 10, and 11 post transplantation, 3. CF2-Crry alone, 4. Anti-C5 alone, 5. B4-Crry + Rapamycin, and 6. Anti-C5 + Rapamycin.
- CR2-Crry was added to the University of Wisconsin (UW) solution which was perfused through the donor. The vessels were clamped and the grafts were stored in UW solution for 6 hours. Living donors (LD) and brain dead (BD) donors were used in the experiments.
- UW University of Wisconsin
- IRI damage was assessed in the vascularized composite allografts from recipients of either living donor or brain dead donor grafts that had either been perfused with UW or UW augmented with CR2-Crry . Histological quantification of injury is shown in skin (Figure 19A) and muscle (Figure 19C) of grafts isolated at 48 hours posttransplant. Representative histological images is shown of skin ( Figure 19B) and muscle ( Figure 19D). It is demonstrated that treatment of BD donors with CR2-Crry significantly decreased skin and muscle histopathological score.
- Figure 20 demonstrates that perfusion of grafts with UW solution augmented with CR2-Crry prolong graft survival of recipients of both living or brain dead donor grafts. There was no significant difference in graft survival in brain dead or living donors.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des compositions et des procédés pour améliorer la survie d'un tissu greffé.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662409187P | 2016-10-17 | 2016-10-17 | |
US62/409,187 | 2016-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018075462A1 true WO2018075462A1 (fr) | 2018-04-26 |
Family
ID=62019300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/056898 WO2018075462A1 (fr) | 2016-10-17 | 2017-10-17 | Compositions et procédés de traitement et de prévention d'une lésion associée à une greffe |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018075462A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109078168A (zh) * | 2018-07-26 | 2018-12-25 | 广西医科大学第附属医院 | 靶向补体抑制剂在制备改善脑死亡供肝药物中的应用 |
WO2020041644A1 (fr) * | 2018-08-22 | 2020-02-27 | Alexion Pharmaceuticals, Inc. | Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant |
WO2021163472A1 (fr) * | 2020-02-14 | 2021-08-19 | The General Hospital Corporation | Surveillance de la viabilité d'organes en vue d'une greffe |
CN114532982A (zh) * | 2022-01-12 | 2022-05-27 | 高谋 | 评价干细胞系统移植调控补体活化作用的体系 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160184391A1 (en) * | 2013-08-16 | 2016-06-30 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
-
2017
- 2017-10-17 WO PCT/US2017/056898 patent/WO2018075462A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160184391A1 (en) * | 2013-08-16 | 2016-06-30 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109078168A (zh) * | 2018-07-26 | 2018-12-25 | 广西医科大学第附属医院 | 靶向补体抑制剂在制备改善脑死亡供肝药物中的应用 |
CN109078168B (zh) * | 2018-07-26 | 2019-09-06 | 广西医科大学第一附属医院 | 靶向补体抑制剂在制备改善脑死亡供肝药物中的应用 |
WO2020041644A1 (fr) * | 2018-08-22 | 2020-02-27 | Alexion Pharmaceuticals, Inc. | Peptides et méthodes de traitement d'affections liées à la dystrophie les utilisant |
WO2021163472A1 (fr) * | 2020-02-14 | 2021-08-19 | The General Hospital Corporation | Surveillance de la viabilité d'organes en vue d'une greffe |
CN114532982A (zh) * | 2022-01-12 | 2022-05-27 | 高谋 | 评价干细胞系统移植调控补体活化作用的体系 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010266127B2 (en) | Methods of stimulating liver regeneration | |
WO2018075462A1 (fr) | Compositions et procédés de traitement et de prévention d'une lésion associée à une greffe | |
US20160184391A1 (en) | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant | |
AU2020200015B2 (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
WO2012139081A2 (fr) | Méthodes de traitement d'états associés à une activation du complément dépendant de masp-2 | |
US11806389B2 (en) | Compositions and methods for treating central nervous system injury | |
US9649357B2 (en) | Treatment of chronic nephropathies using soluble complement receptor type I (sCR1) | |
JP6771568B2 (ja) | 補体活性化を抑制するポリペプチド | |
US20190247511A1 (en) | Compositions and methods for treating and preventing transplant-associated injury | |
KR20210018294A (ko) | 이식편 대 숙주 질환 및 점막염의 예방 및 치료를 위한 cd24의 사용 방법 | |
AU2011319746B2 (en) | Method of improving transplant function using soluble complement receptor type I (sCR1) | |
JP2012530106A (ja) | HLA−Gα1多量体及びその薬学的使用 | |
WO2018075450A1 (fr) | Compositions et procédés de traitement d'une lésion du système nerveux central |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17861528 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17861528 Country of ref document: EP Kind code of ref document: A1 |